Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 64
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lamivudine modulates the expression of neurological impairment-related genes and LINE-1 retrotransposons in brain tissues of a Down syndrome mouse model

  • Borgognone, Alessandra|||0000-0001-5487-3016
  • Casadellà, Maria|||0000-0002-4115-2305
  • Martínez de Lagrán, María|||0000-0002-0836-6491
  • Paredes, Roger|||0000-0002-6553-691X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Dierssen, Mara|||0000-0003-0853-6865
  • Elizalde-Torrent, Aleix|||0000-0001-7405-777X
Elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases, including Down syndrome (DS), which is the most common chromosomal condition causing intellectual disability globally. Previous research by our group has revealed that treatment with lamivudine, a reverse transcriptase inhibitor, improved neurobehavioral phenotypes and completely rescued hippocampal-dependent recognition memory in a DS mouse model, Ts65Dn. We hypothesized that retrotransposition rates would increase in the Ts65Dn mouse model, and lamivudine could block retrotransposons. We analyzed the differentially expressed long interspersed element-1 (LINE-1 or L1) mapping on MMU16 and 17, and showed for the first time that retrotransposition could be associated with Ts65Dn's pathology, as misregulation of L1 was found in brain tissues associated with trisomy. In the cerebral cortex, 6 out of 26 upregulated L1s in trisomic treated mice were located in the telomeric region of MMU16 near Ttc3, Kcnj6, and Dscam genes. In the hippocampus, one upregulated L1 element in trisomic treated mice was located near the Fgd4 gene on MMU16. Moreover, two downregulated L1s rescued after treatment with lamivudine were located in the intronic region of Nrxn1 (MMU17) and Snhg14 (MMU7), implicated in a variety of neurodegenerative disorders. To gain further insight into the mechanism of this improvement, we here analyzed the gene expression profile in the hippocampus and cerebral cortex of trisomic mice treated and no-treated with lamivudine compared to their wild-type littermates. We found that treatment with lamivudine rescued the expression of 24% of trisomic genes in the cortex (located on mouse chromosome (MMU) 16 and 17) and 15% in the hippocampus (located in the human chromosome 21 orthologous regions), with important DS candidate genes such as App and Ets2, rescued in both regions.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Astrocytopathy is associated with CA1 synaptic dysfunction in a mouse model of Down syndrome

  • Fernández-Blanco, Álvaro
  • González-Arias, Candela
  • Sierra, Cesar
  • Zamora Moratalla, Alfonsa
  • Perea, Gertrudis
  • Dierssen, Mara
Brain pathophysiology in Down syndrome (DS), the most common genetic cause of intellectual disability, has traditionally been considered a consequence of neuronal dysfunction. However, although it is well documented that astrocytes play a critical role in brain homeostasis, synaptic regulation, and neuronal support, and their malfunction has been associated with the onset and progression of different neurological disorders, only a few studies have addressed whether astrocyte dysfunction can contribute to the DS pathophysiology. Astrocytes are increased in number and size, and show increased levels of expression of astroglial markers like S100ß and GFAP. In this study, we detected a region-specific increase in astrocyte population in CA1 and, to a lesser extent, in the dentate gyrus. Single-nucleus transcriptomic profiling identified markers associated with reactive astroglia, synaptic transmission, and neuroinflammation in trisomic astrocytes. Functional analysis revealed abnormal Ca2+ oscillations in trisomic astrocytes and impaired astrocyte-to-neuron communication in CA1, the most affected subregion, leading to astrocyte-mediated excitatory synaptic depression. Our findings demonstrate that astrocytes play an active and critical role in the pathophysiology of DS, not only as reactive responders to neuronal injury but as key contributors to the disease process itself. This astrocytic dysfunction presents a region-specific distribution within the hippocampus, suggesting localized vulnerability and complex glial involvement in DS-related neuropathology., The lab of MD is supported by the Secretaria d¿Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS funded by MICIU/AEI/10.13039/501100011033/FEDER, UE). This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848077). The publication is part of the grant PRE2018-084504, funded by MCIN/AEI/10.13039/501100011033 and by the FSE+ (AFB). Additionally, we have been supported by Fundació La Marató TV3 (201620-31 and 225619), and by PID2022-142617NB-I00 and PID2019-106579RB-I00 funded by MCIN/AEI/10.13039/501100011033 to G.P.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Comparison of COVID-19 and non-COVID-19 pneumonia in Down syndrome

  • Real de Asua, Diego
  • Mayer, Miguel Ángel, 1960-
  • Ortega, María del Carmen
  • Borrel, Jose M.
  • Bermejo, Teresa de Jesús
  • González Lamuño, Domingo
  • Manso, Coral
  • Moldenhauer, Fernando
  • Carmona Iragui, María
  • Hüls, Anke
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID-19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19., The lab of M.D. is supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). We also acknowledge the support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848077, Jerôme Lejeune Foundation (No 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), JPND Heroes project. CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) and CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN) are initiatives of the ISCIII. D.R.A. is partially supported by the Fondo de Investigaciones Sanitarias (FIS grant PI19/00634, European Fund for Regional Development—EFRD) and the Foundation Jérôme Lejeune (grant no. 1777-2018). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). AH was supported by the HERCULES Center (NIEHS P30ES019776) and by the LuMind IDSC Foundation.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Re-establishment of the epigenetic state and rescue of kinome deregulation in Ts65Dn mice upon treatment with green tea extract and environmental enrichment

  • De Toma, Ilario
  • Ortega, M.
  • Catuara Solarz, Silvina, 1986-
  • Sierra, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Down syndrome (DS) is the main genetic cause of intellectual disability due to triplication of human chromosome 21 (HSA21). Although there is no treatment for intellectual disability, environmental enrichment (EE) and the administration of green tea extracts containing epigallocatechin-3-gallate (EGCG) improve cognition in mouse models and individuals with DS. Using proteome, and phosphoproteome analysis in the hippocampi of a DS mouse model (Ts65Dn), we investigated the possible mechanisms underlying the effects of green tea extracts, EE and their combination. Our results revealed disturbances in cognitive-related (synaptic proteins, neuronal projection, neuron development, microtubule), GTPase/kinase activity and chromatin proteins. Green tea extracts, EE, and their combination restored more than 70% of the phosphoprotein deregulation in Ts65Dn, and induced possible compensatory effects. Our downstream analyses indicate that re-establishment of a proper epigenetic state and rescue of the kinome deregulation may contribute to the cognitive rescue induced by green tea extracts., This work was supported by the Fondation Jérôme Lejeune Foundation (Project #1347 “Elucidation of the mechanism of action of epigallocatechin-3-gallate as a therapeutic agent on the cognitive phenotype in Down Syndrome mice models”), Agencia Estatal de Investigación (AEI) (PID2019-110755RB-I00/AEI/10.13039/501100011033), H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21-848077, Fundació La Marató De TV3 (201620-31_MDierssen), EU (JPND HEROES (tHE cRossroad Of dEmentia Syndromes), NIH (Grant Number: 1R01EB 028159-01). The CRG is a Center of Excellence Severo Ochoa. The CIBER of Rare Diseases is an initiative of the ISCIII. The laboratories of M. Dierssen and E. Sabidó are supported by DIUE de la Generalitat de Catalunya (Grups consolidats 2017SGR926, 2017SGR595). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Modeling the impact of neuromorphological alterations in Down syndrome on fast neural oscillations

  • Clusella, Pau
  • Manubens-Gil, Linus, 1989-
  • García Ojalvo, Jordi
  • Dierssen, Mara
Cognitive disorders, including Down syndrome (DS), present significant morphological alterations in neuron architectural complexity. However, the relationship between neuromorphological alterations and impaired brain function is not fully understood. To address this gap, we propose a novel computational model that accounts for the observed cell deformations in DS. The model consists of a cross-sectional layer of the mouse motor cortex, composed of 3000 neurons. The network connectivity is obtained by accounting explicitly for two single-neuron morphological parameters: the mean dendritic tree radius and the spine density in excitatory pyramidal cells. We obtained these values by fitting reconstructed neuron data corresponding to three mouse models: wild-type (WT), transgenic (TgDyrk1A), and trisomic (Ts65Dn). Our findings reveal a dynamic interplay between pyramidal and fast-spiking interneurons leading to the emergence of gamma activity (∼40 Hz). In the DS models this gamma activity is diminished, corroborating experimental observations and validating our computational methodology. We further explore the impact of disrupted excitation-inhibition balance by mimicking the reduction recurrent inhibition present in DS. In this case, gamma power exhibits variable responses as a function of the external input to the network. Finally, we perform a numerical exploration of the morphological parameter space, unveiling the direct influence of each structural parameter on gamma frequency and power. Our research demonstrates a clear link between changes in morphology and the disruption of gamma oscillations in DS. This work underscores the potential of computational modeling to elucidate the relationship between neuron architecture and brain function, and ultimately improve our understanding of cognitive disorders., PC and JGO have received funding from the Future and Emerging Technologies Programme (FET) of the European Union’s Horizon 2020 research and innovation programme (project NEUROTWIN, grant agreement No 101017716). JGO was also financially supported by the Spanish Ministry of Science and Innovation (project reference PID2021-127311NB-I00), the FEDER funds of the Spanish State Research Agency (project reference MICIN/AEI/10.13039/501100011033/FEDER), the Maria de Maeztu Programme for Units of Excellence in R\&D of the Spanish State Research Agency (project reference CEX2018-000792-M), and by the ICREA Academia program. LMG was supported by the National Natural Science Foundation of China (RFIS-I grant, reference 32350410413). MD acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dietary patterns and lifestyle factors as determinants of body mass index and body composition in individuals with Down Syndrome-A study across three clinical sites

  • Gomis González, Maria, 1988-
  • Boronat Rigol, Anna, 1990-
  • Langohr, Klaus
  • Bianchi, Leda A.
  • Wells, Jasmine
  • Tamayo-Elizalde, Miren
  • Ben Smida, Inés
  • Verdun, Laude De
  • Chan, Li
  • Hiance-Delahaye, Anna
  • Strydom, Andre
  • Torre Fornell, Rafael de la
  • Go-Ds Consortium
Background/Objectives: It is often reported in the literature that the prevalence of obesity is high in individuals with Down Syndrome (DS). This study aims to assess how lifestyle factors-diet quality, nutrient intake or physical activity-contribute to weight gain. Methods: 230 males/females with DS, aged 12-45 years, were recruited across three geographically independent sites. A total of 185 participants were considered for this analysis and classified into normal-weight, overweight, and obese categories. Diet quality and nutrient intake were calculated using country-specific FFQs. Physical activity was assessed with the Minnesota Leisure Time Activity Questionnaire. Body composition measures were obtained with a bioimpedance scale. Results: The study corroborates a higher prevalence (%) of overweight/obesity in our DS cohort compared to the general population. Higher BMIs were significantly correlated with older age (p < 0.001), lower physical activity (p < 0.05), higher parental BMIs (p < 0.001, mother's BMI; p < 0.05, father's BMI), and increased adiposity indicators. Excess body weight showed an inverse association only with protein intake (p < 0.001). No significant differences emerged in total caloric or other macronutrients intake across BMI categories. However, notable differences in dietary patterns were observed among the three countries, reflecting cultural influences. A smaller exploratory sub-study suggested a potential relationship between higher IQ scores and better diet quality (p < 0.05). Conclusions: These findings provide new insights into contributors to overweight/obesity in DS people, indicating an influence of age, physical activity, familial factors, and body composition. Higher protein intake and culturally adapted lifestyle interventions may contribute to improving weight-related outcomes., The Gene Overdosage and Comorbidities During the Early Lifetime in Down Syndrome (GO-DS21) project has received funding from the European Union's Horizon research and innovation program under grant agreement n- SC1848077. The CIBEROBN is an initiative of the ISCIII. This work was supported by grants from DIUE de la Generalitat de Catalunya (2021SGR00253) and from the Ministerio de Ciencia, Innovanción y Universidades (PID2023-148033OB-C21). LFC received funding from a Medical Research Council UK and Academy of Medical Sciences fellowship grant (G0802796), aWellcome Trust grant (217543/Z/19/Z), BBSRC (BB/W018276/1), and Barts Charity grant (G-002162). AS received funding from the Jerome Lejeune Foundation, and the MRC (grant numbers MR/S011277/1, MR/S005145/1, and MR/R024901/1).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Meta-analysis of transcriptomic data reveals clusters of consistently deregulated gene and disease ontologies in Down syndrome

  • De Toma, Ilario
  • Sierra, Cesar
  • Dierssen, Mara
Trisomy of human chromosome 21 (HSA21) causes Down syndrome (DS). The trisomy does not simply result in the upregulation of HSA21--encoded genes but also leads to a genome-wide transcriptomic deregulation, which affect differently each tissue and cell type as a result of epigenetic mechanisms and protein-protein interactions. We performed a meta-analysis integrating the differential expression (DE) analyses of all publicly available transcriptomic datasets, both in human and mouse, comparing trisomic and euploid transcriptomes from different sources. We integrated all these data in a "DS network". We found that genome wide deregulation as a consequence of trisomy 21 is not arbitrary, but involves deregulation of specific molecular cascades in which both HSA21 genes and HSA21 interactors are more consistently deregulated compared to other genes. In fact, gene deregulation happens in "clusters", so that groups from 2 to 13 genes are found consistently deregulated. Most of these events of "co-deregulation" involve genes belonging to the same GO category, and genes associated with the same disease class. The most consistent changes are enriched in interferon related categories and neutrophil activation, reinforcing the concept that DS is an inflammatory disease. Our results also suggest that the impact of the trisomy might diverge in each tissue due to the different gene set deregulation, even though the triplicated genes are the same. Our original method to integrate transcriptomic data confirmed not only the importance of known genes, such as SOD1, but also detected new ones that could be extremely useful for generating or confirming hypotheses and supporting new putative therapeutic candidates. We created "metaDEA" an R package that uses our method to integrate every kind of transcriptomic data and therefore could be used with other complex disorders, such as cancer. We also created a user-friendly web application to query Ensembl gene IDs and retrieve all the information of their differential expression across the datasets., Funding: The lab of MD is supported by the Departament d'Universitats, Recerca i Societat de la Informació (DURSI) de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We acknowledge the support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/ 10.13039/501100011033), H2020 SC1 (GO-DS21- 848077), Jerôme Lejeune Foundation (#2002), NIH (#1R01EB 028159-01), Fundació La Marató-TV3 (#2016/20-30), JPND Heroes AC170006 Ministerio de Ciencia Innovación y Universidades (#RTC2019-007230-1 and #RTC2019-007329-1). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

COVID-19 vaccination of individuals with Down syndrome-data from the trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to be Vaccinated

  • Hüls, Anke
  • Dierssen, Mara
  • Strydom, Andre
Individuals with Down syndrome (DS) are among the groups with the highest risk for severe COVID-19. Better understanding of the efficacy and risks of COVID-19 vaccines for individuals with DS may help improve uptake of vaccination. The T21RS COVID-19 Initiative launched an international survey to obtain information on safety and efficacy of COVID-19 vaccines for individuals with DS. De-identified survey data collected between March and December 2021 were analyzed. Of 2172 individuals with DS, 1973 (91%) had received at least one vaccine dose (57% BNT162b2), 107 (5%) were unvaccinated by choice, and 92 (4%) were unvaccinated for other reasons. Most participants had either no side effects (54%) or mild ones such as pain at the injection site (29%), fatigue (12%), and fever (7%). Severe side effects occurred in <0.5% of participants. About 1% of the vaccinated individuals with DS contracted COVID-19 after vaccination, and all recovered. Individuals with DS who were unvaccinated by choice were more likely to be younger, previously recovered from COVID-19, and also unvaccinated against other recommended vaccines. COVID-19 vaccines have been shown to be safe for individuals with DS and effective in terms of resulting in minimal breakthrough infections and milder disease outcomes among fully vaccinated individuals with DS., This work is supported by grants from: Down Syndrome Affiliates in Action, Down Syndrome Medical Interest Group-USA, GiGi’s Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, National Down Syndrome Society, National Task Group on Intellectual Disabilities and Dementia Practices. AH is supported by the HERCULES Center (NIEHS P30ES019776). AH and PTF are supported by the LuMind IDSC Foundation. The REDCap survey and database management system at Emory University was supported by Library Information Technology Services grant support (UL1 TR000424). MD is supported by the Centre for Genomic Regulation Severo Ochoa excellence grant, the CIBER of Rare Diseases, DURSI 2017SGR595, and acknowledges support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the Spanish Ministry of Science, Innovation and Universities (MSIU) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and CERCA (GenCat). AS is supported by the MRC (MR/S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The Lejeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21-848077). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). DRA was supported by the Fondo de Investigaciones Sanitarias (grant PI19/00634, from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional Development Fund (ERDF) “A way to make Europe”) and the Fondation Jérôme Lejeune (grant no. 2021a-2069)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Differences in clinical presentation, severity, and treatment of COVID-19 among individuals with Down syndrome from India and high-income countries: Data from the Trisomy 21 Research Society survey

  • Pinku, Halder
  • Hüls, Anke
  • Feany, Patrick T.
  • Baumer, Nicole
  • Dierssen, Mara
  • Bargagna, Stefania
  • Costa, Alberto C.S.
  • Chicoine, Brian Allen
  • Rebillat, Anne-Sophie
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Rohrer, R. Tilman
  • Levin, Johannes
  • Lakhanpaul, Monica
  • Carfì, Angelo
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Ghosh, Sujay
  • Trisomy Research Society Covid-Initiative Study Group
Background: People with Down syndrome (DS) are one of the highest risk groups for mortality associated with COVID-19, but outcomes may differ across countries due to different co-morbidity profiles, exposures, and societal practices, which could have implications for disease management. This study is designed to identify differences in clinical presentation, severity, and treatment of COVID-19 between India and several high-income countries (HICs). Methods: We used data from an international survey to examine the differences in disease manifestation and management for COVID-19 patients with DS from India vs HIC. De-identified survey data collected from April 2020 to August 2021 were analysed. Results: COVID-19 patients with DS from India were on average nine years younger than those from HICs. Comorbidities associated with a higher risk for severe COVID-19 were more frequent among the patients from India than from HICs. Hospitalizations were more frequent among patients from India as were COVID-19-related medical complications. Treatment strategies differed between India and HICs, with more frequent use of antibiotics in India. The average severity score of 3.31 was recorded for Indian DS in contrast to 2.3 for European and 2.04 for US cases. Conclusions: Presentation and outcomes of COVID-19 among individuals with DS were more severe for patients from India than for those from HIC. Global efforts should especially target vaccination campaigns and other risk-reducing interventions for individuals with DS from low-income countries., PH is supported by University Grant Commission, India (UGC/21/06/2015 (i)EU-V). SG is supported by Government of West Bengal (DST, WB) Grant No. SG/WBDST/S&T 1000114/2016 and UGC-UPEII, DST-PURSE programs (Grant No. UGC/859/UPE-2 BIO). AH is supported by the HERCULES Center (NIEHS P30ES019776) and the LuMind IDSC Foundation. The REDCap survey and database management system at Emory University was supported by Library Information Technology Services grant support (UL1 TR000424). ACSC is supported by the Alana USA Foundation, Awakening Angels Foundation, and the Infectious Diseases Society of America (IDSA). MD is supported by the Centre for Genomic Regulation Severo Ochoa excellence grant, the CIBER of Rare Diseases, DURSI 2017SGR595, and acknowledges the Spanish Ministry of Science, Innovation and Universities (MSIU) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and CERCA (GenCat). AS is supported by the MRC (MR/ S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The LeJeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down syndrome GO-DS21- 848077). ML was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust). DRdeA was partially supported by Spanish Fondo de Investigacion Sanitaria-Instituto Carlos III (FIS-ISCIII), grant No. PI19/00634; BAC has research support from Various Grateful Families of Patients. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/ 0014). The DCEXS is a ‘Unidad de Excelencia Marí a de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agencia de G d ’AjutsUniversitarisi de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). This study was also supported by the Fondo de InvestigacionesSanitario (FIS), Instituto de Salud Carlos III (PI18/00335 to MCI, PI14/ 01126 and PI17/01019 to JF), partly jointly funded by Fondo Europeo de Desarrollo Regional, Union Europea, Una manera de hacer Europa; the Jerome Lejeune Foundation (No.1319 Cycle 2019B to MCI); the National Institutes of Health (NIA grants 1R01AG056850 – 01A1; R21AG056974 and R01AG061566 to JF); Departament de Salut de la Generalitat de Catalunya, PlaEstrategic de RecercaiInnovaci o enSalut (SLT006/17/00119 to JF); and Fundacio La Marat o de TV3 (20141210 to JF).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Fluorescent transgenic mouse models for whole-brain imaging in health and disease

  • Arias, Adrian
  • Manubens-Gil, Linus, 1989-
  • Dierssen, Mara
A paradigm shift is occurring in neuroscience and in general in life sciences converting biomedical research from a descriptive discipline into a quantitative, predictive, actionable science. Living systems are becoming amenable to quantitative description, with profound consequences for our ability to predict biological phenomena. New experimental tools such as tissue clearing, whole-brain imaging, and genetic engineering technologies have opened the opportunity to embrace this new paradigm, allowing to extract anatomical features such as cell number, their full morphology, and even their structural connectivity. These tools will also allow the exploration of new features such as their geometrical arrangement, within and across brain regions. This would be especially important to better characterize brain function and pathological alterations in neurological, neurodevelopmental, and neurodegenerative disorders. New animal models for mapping fluorescent protein-expressing neurons and axon pathways in adult mice are key to this aim. As a result of both developments, relevant cell populations with endogenous fluorescence signals can be comprehensively and quantitatively mapped to whole-brain images acquired at submicron resolution. However, they present intrinsic limitations: weak fluorescent signals, unequal signal strength across the same cell type, lack of specificity of fluorescent labels, overlapping signals in cell types with dense labeling, or undetectable signal at distal parts of the neurons, among others. In this review, we discuss the recent advances in the development of fluorescent transgenic mouse models that overcome to some extent the technical and conceptual limitations and tradeoffs between different strategies. We also discuss the potential use of these strains for understanding disease., The lab of MD was supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 848077. This reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant Number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and JPND (Heroes AC170006). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Social factors influence behavior in the novel object recognition task in a mouse model of down syndrome

  • Sierra, Cesar
  • De Toma, Ilario
  • Lo Cascio, Lorenzo
  • Vegas, Esteban
  • Dierssen, Mara
The use of mouse models has revolutionized the field of Down syndrome (DS), increasing our knowledge about neuropathology and helping to propose new therapies for cognitive impairment. However, concerns about the reproducibility of results in mice and their translatability to humans have become a major issue, and controlling for moderators of behavior is essential. Social and environmental factors, the experience of the researcher, and the sex and strain of the animals can all have effects on behavior, and their impact on DS mouse models has not been explored. Here we analyzed the influence of a number of social and environmental factors, usually not taken into consideration, on the behavior of male and female wild-type and trisomic mice (the Ts65Dn model) in one of the most used tests for proving drug effects on memory, the novel object recognition (NOR) test. Using principal component analysis and correlation matrices, we show that the ratio of trisomic mice in the cage, the experience of the experimenter, and the timing of the test have a differential impact on male and female and on wild-type and trisomic behavior. We conclude that although the NOR test is quite robust and less susceptible to environmental influences than expected, to obtain useful results, the phenotype expression must be contrasted against the influences of social and environmental factors., The lab of MD is supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 848077. Jerôme Lejeune Foundation (Grant number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and JPND (Heroes; AC17/00006). The Centre for Genomic Regulation (CRG) acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII. CS received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Methods for identifying epilepsy surgery targets using invasive EEG: a systematic review

  • Ivankovic, Karla
  • Principe, Alessandro
  • Zucca, Riccardo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
Background: The pre-surgical evaluation for drug-resistant epilepsy achieves seizure freedom in only 50-60% of patients. Efforts to identify quantitative intracranial EEG (qEEG) biomarkers of epileptogenicity are needed. This review summarizes and evaluates the design of qEEG studies, discusses barriers to biomarker adoption, and proposes refinements of qEEG study protocols. Methods: We included exploratory and prediction prognostic studies from MEDLINE and Scopus published between 2017 and 2023 that investigated qEEG markers for identifying the epileptogenic network as the surgical target. Cohort parameters, ground truth references, and analytical approaches were extracted. Results: Out of 1789 search results, 128 studies were included. The study designs were highly heterogeneous. Half of the studies included a non-consecutive cohort, with sample sizes ranging from 2 to 166 patients (median of 16). The most common minimum follow-up was one year, and the seizure onset zone was the most common ground truth. Prediction studies were heterogeneous in their analytical approaches, and only 25 studies validated the marker through post-surgical outcome prediction. Outcome prediction performance decreased in larger cohorts. Conversely, longer follow-up periods correlated with higher prediction accuracy, and connectivity-based approaches yielded better predictions. The data and code were available in only 9% of studies. Conclusions: To enhance the validation qEEG markers, we propose standardizing study designs to resemble clinical trials. This includes using a consecutive cohort with long-term follow-up, validating against surgical resection as ground truth, and evaluating markers through post-surgical outcome prediction. These considerations would improve the reliability and clinical adoption of qEEG markers., K.I. is supported by Ajuts Destinats a Universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802). A.P. is supported by Fundación Tatiana-Proyectos en Neurociencia (Grant 2022-1514). R.Z. is supported by Neurotech-EU (Grant agreement ID: 101035817). M.D. is funded by the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS), H2020 European Union's Horizon 2020 research and innovation programme under grant agreement No. 848077 and 899986, Jerôme Lejeune Foundation #2002. The APC was funded by Fundación Tatiana¿Proyectos en Neurociencia (Grant 20.22-15.14).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

  • Hüls, Anke
  • Dierssen, Mara
  • Mayer, Miguel Ángel, 1960-
  • T21RS COVID-19 Initiative
Background: Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. Methods: The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. Findings: The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Interpretation: Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Funding: Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Rethinking intellectual disability from neuro- to astro-pathology

  • Fernández-Blanco, Álvaro
  • Dierssen, Mara
Neurodevelopmental disorders arise from genetic and/or from environmental factors and are characterized by different degrees of intellectual disability. The mechanisms that govern important processes sustaining learning and memory, which are severely affected in intellectual disability, have classically been thought to be exclusively under neuronal control. However, this vision has recently evolved into a more integrative conception in which astroglia, rather than just acting as metabolic supply and structural anchoring for neurons, interact at distinct levels modulating neuronal communication and possibly also cognitive processes. Recently, genetic tools have made it possible to specifically manipulate astrocyte activity unraveling novel functions that involve astrocytes in memory function in the healthy brain. However, astrocyte manipulation has also underscored potential mechanisms by which dysfunctional astrocytes could contribute to memory deficits in several neurodevelopmental disorders revealing new pathogenic mechanisms in intellectual disability. Here, we review the current knowledge about astrocyte dysfunction that might contribute to learning and memory impairment in neurodevelopmental disorders, with special focus on Fragile X syndrome and Down syndrome., Funding: The lab of MD is supported by the CRG Severo Ochoa excellence grant, the CIBER of Rare Diseases and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21- 848077, Jerôme Lejeune Foundation, NIH (Grant Number: 1R01EB 028159-01), Marató TV3, JPND Heroes project, and the Spanish Ministry of Science and Innovation (MICINN) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

COVID-19 in children with down syndrome: data from the trisomy 21 Research Society Survey

  • Emes, David
  • Hüls, Anke
  • Baumer, Nicole
  • Dierssen, Mara
  • Puri, Shiela
  • Russell, Lauren
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Bargagna, Stefania
  • Brandão, Ana Cláudia
  • Costa, Alberto C.S.
  • Feany, Patrick T.
  • Chicoine, Brian Allen
  • Ghosh, Sujay
  • Rebillat, Anne-Sophie
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Roher, Tilman R.
  • Levin, Johannes
  • Lakhanpaul, Monica
  • Trisomy Research Society Covid-Initiative Study Group
Adults with Down Syndrome (DS) are at higher risk for severe outcomes of coronavirus disease 2019 (COVID-19) than the general population, but evidence is required to understand the risks for children with DS, which is necessary to inform COVID-19 shielding advice and vaccination priorities. We aimed to determine the epidemiological and clinical characteristics of COVID-19 in children with DS. Using data from an international survey obtained from a range of countries and control data from the United States, we compared the prevalence of symptoms and medical complications and risk factors for severe outcomes between DS and non-DS paediatric populations with COVID-19. Hospitalised COVID-19 patients <18 years with DS had a higher incidence of respiratory symptoms, fever, and several medical complications from COVID-19 than control patients without DS <18 years. Older age, obesity, and epilepsy were significant risk factors for hospitalisation among paediatric COVID-19 patients with DS, and age and thyroid disorder were significant risk factors for acute respiratory distress syndrome. Mortality rates were low in all paediatric COVID-19 patients (with and without DS), contrasting with previous findings in adults with DS (who exhibit higher mortality than those without DS). Children with DS are at increased risk for more severe presentations of COVID-19. Efforts should be made to ensure the comprehensive and early detection of COVID-19 in this population and to identify children with DS who present comorbidities that pose a risk for a severe course of COVID-19. Our results emphasize the importance of vaccinating children with DS as soon as they become eligible., This work is supported by grants from the following bodies: Down Syndrome Affiliates in Action, Down Syndrome Medical Interest Group-USA, GiGi’s Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, National Down Syndrome Society, National Task Group on Intellectual Disabilities and Dementia Practices. AH is supported by the HERCULES Center (NIEHS P30ES019776). The REDCap survey and database management system at Emory University was supported by Library Information Technology Services grant support (UL1 TR000424). MD is supported by the Centre for Genomic Regulation Severo Ochoa excellence grant, the CIBER of Rare Diseases, and DURSI 2017SGR595, and acknowledges the Spanish Ministry of Science, Innovation and Universities (MSIU) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and CERCA (GenCat). AS is supported by the MRC (MR/S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The LeJeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21- 848077). ML was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). This study was also supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI18/00335 to MCI, PI14/01126 and PI17/01019 to JF), partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa; the Jérôme Lejeune Foundation (No. 1319 Cycle 2019B to MCI); the National Institutes of Health (NIA grants 1R01AG056850 - 01A1; R21AG056974 and R01AG061566 to JF); Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (SLT006/17/00119 to JF); and Fundació La Marató de TV3 (20141210 to JF)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome

  • Martínez de Lagrán Cabredo, María
  • Elizalde-Torrent, Aleix
  • Paredes, Roger
  • Clotet, Bonaventura
  • Dierssen, Mara
An elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases. Down syndrome (DS) is the most common genetic disorder associated with intellectual disability and a genetic form of Alzheimer's disease. For this reason, we hypothesized that treatment with reverse transcriptase inhibitors could ameliorate DS phenotypes. In this proof of concept study, we treated trisomic (Ts65Dn) mice, a model of DS, with lamivudine, a reverse transcriptase inhibitor. We detected a significant improvement of neurobehavioural phenotypes, and a complete rescue of the hippocampal-dependent recognition memory upon treatment with lamivudine. Despite clinical studies in patients with DS are warranted, this study lays the groundwork for a novel and actionable therapeutic approach., Agencia Estatal de Investigación. Grant Number: PID2019-110755RB-I00/AEI/10.13039/501100011033. Horizon 2020 Framework Programme. Grant Number: 848077
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Understanding obesity in individuals with down syndrome: caregiver perceptions, awareness, and motivation

  • Cahill, Thomas
  • Nalesso, Valerie
  • Clarke, Pat
  • Martínez de Lagrán Cabredo, María
  • Strydom, Andre
  • Chan, Li
  • Potier, Marie-Claude
  • Beckers, Johannes
  • Langohr, Klaus
  • Liò, Pietro
  • Torre Fornell, Rafael de la
  • Forcano, Laura
  • Hiance-Delahaye, Anna
  • Herault, Yann
  • Dierssen, Mara
Background: Individuals with Down syndrome (DS) are at an increased risk of obesity and, subsequently, its cardiometabolic and cognitive impacts. Caregivers play a critical role in managing health, yet their perceptions and behaviors have been poorly characterized. Methods: We performed a cross-sectional online survey of caregivers (n = 764) taking care of 48% females and 52% males with DS, conducted across European populations, predominantly in Spain and France. We assessed perceived obesity, perceived harmfulness of current weight, professional consultation, and confidence in promoting healthy behaviors. Associations were examined using chi-square tests, correlation analysis, and ordinal and logistic regression models. Results: Around one-third (32%) of caregivers perceived their family member with DS with obesity. Perceived obesity changed with age and was more frequently reported in female family members with DS. Awareness of general metabolic risk factors was high among caregivers, but half of respondents were unaware that abdominal fat affects brain health. Consultation with healthcare professionals was uncommon (57% "Never/Rarely/Sometimes") even among those perceived with obesity. Conclusions: Caregivers demonstrate good general awareness about high energy food risks but limited knowledge of the link between obesity and brain health. Enhancing caregiver education and supporting behavioral change could promote healthier lifestyles in families with individuals with DS., This project received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 848077 (GO-DS21). The lab of M.D. and of RTF are recognized by the Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), the Generalitat de Catalunya through the CERCA program and the EMBL partnership. KL received funding from PID2023-148033OB-C21 of the Ministerio de Ciencia, Innovación y Universidades (Spain; MICIU/AEI/10.13039/501100011033) and the European Regional development Fund (FEDER). LC received funding from Wellcome Trust grant (217543/Z/19/Z), and Barts Charity grant (G-002162). AS received funding from Medical Research Council grants (MR/S011277/1, MR/S005145/1, and MR/R024901/1) and the Jerome LeJeune Foundation. MD received funding from the Agencia Estatal de Investigación (PID2022-141900OB-I00 funded by MICIU/AEI/10.13039/501100011033/ERDF, EU), Fundació La Marató-TV3 (#202212-30), Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1, and CPP2022-009659 funded by MCIN/AEI/10.13039/501100011033 and EU's 'NextGenerationEU'/PRTR'). The CIBER of Rare Diseases is an initiative of the ISCIII. RDT and LF research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A highly conserved neuronal microexon in DAAM1 controls actin dynamics, RHOA/ROCK signaling, and memory formation

  • Poliński, Patryk
  • Miret-Cuesta, Marta
  • Zamora Moratalla, Alfonsa
  • Mantica, Federica
  • Cantero Recasens, Gerard, 1984-
  • Viana, Carlotta
  • Sabariego Navarro, Miguel
  • Normanno, Davide
  • Iñiguez, Luis P.
  • Bonnal, Sophie
  • Gómez-Riera, Raúl
  • Fanlo-Ucar, Hugo
  • Yap, Dominic S.
  • Martínez de Lagrán Cabredo, María
  • Fernández-Blanco, Álvaro
  • Rodríguez-Marin, Cristina
  • Permanyer, Jon
  • Fölsz, Orsolya
  • Domínguez-Sala, Eduardo
  • Sierra, Cesar
  • Wojnacki, José
  • Musoles Lleo, Juan Luis
  • Cosma, Maria Pia
  • Muñoz López, Francisco José, 1964-
  • Dierssen, Mara
  • Irimia Martínez, Manuel
Actin cytoskeleton dynamics is essential for proper nervous system development and function. A conserved set of neuronal-specific microexons influences multiple aspects of neurobiology; however, their roles in regulating the actin cytoskeleton are unknown. Here, we study a microexon in DAAM1, a formin-homology-2 (FH2) domain protein involved in actin reorganization. Microexon inclusion extends the linker region of the DAAM1 FH2 domain, altering actin polymerization. Genomic deletion of the microexon leads to neuritogenesis defects and increased calcium influx in differentiated neurons. Mice with this deletion exhibit postsynaptic defects, fewer immature dendritic spines, impaired long-term potentiation, and deficits in memory formation. These phenotypes are associated with increased RHOA/ROCK signaling, which regulates actin-cytoskeleton dynamics, and are partially rescued by treatment with a ROCK inhibitor. This study highlights the role of a conserved neuronal microexon in regulating actin dynamics and cognitive functioning., The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERCCoG-LS2-101002275 to M.I.), Spanish Ministry of Science and Innovation (PID2020-115040GB-I00 to M.I., PID2022−141900OB-I00 to M.D., PID2020- 114080GB-I00 to M.P.C., PID2023-1497670B-I00 to F.J.M. and PID2022-138245NB-I00 to E.H), the European Union’s Horizon 2020 research and innovation program under grant agreements No 964342 to M.P.C., 721890 to P.P. and 848077 to A.Z.M., the National Institutes of Health (NIH) (1R01NS137222-01 to M.D.) and AGAUR grants from Secretaria d’Universitats i Recerca del Departament d’Empresa iConeixement de la Generalitat de Catalunya to M.I., M.D. and M.P.C.. CRG acknowledges support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. M.S.N. received an FPU fellowship (FPU19/04789) from Ministerio de Universidades. This research was in part supported by grants from the Simons Foundation and Canadian Institutes of Health Research to B.J.B., who also holds the University of Toronto Banbury Chair in Medical Research and the Canada Research Chair in RNA Biology and Genomics.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2024 update

  • Martínez de Lagrán Cabredo, María
  • Bascón-Cardozo, Karen
  • Dierssen, Mara
Neurodevelopmental disorders encompass a range of conditions such as intellectual disability, autism spectrum disorder, rare genetic disorders and developmental and epileptic encephalopathies, all manifesting during childhood. Over 1,500 genes involved in various signaling pathways, including numerous transcriptional regulators, spliceosome elements, chromatin-modifying complexes and de novo variants have been recognized for their substantial role in these disorders. Along with new machine learning tools applied to neuroimaging, these discoveries facilitate genetic diagnoses, providing critical insights into neuropathological mechanisms and aiding in prognosis, and precision medicine. Also, new findings underscore the importance of understanding genetic contributions beyond protein-coding genes and emphasize the role of RNA and non-coding DNA molecules but also new players, such as transposable elements, whose dysregulation generates gene function disruption, epigenetic alteration, and genomic instability. Finally, recent developments in analyzing neuroimaging now offer the possibility of characterizing neuronal cytoarchitecture in vivo, presenting a viable alternative to traditional post-mortem studies. With a recently launched digital atlas of human fetal brain development, these new approaches will allow answering complex biological questions about fetal origins of cognitive function in childhood. In this review, we present ten fascinating topics where major progress has been made in the last year., The lab of M.D. acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Down syndrome and obesity management: lifestyle observations made in the framework of the GO-DS21 project and clinical recommendations

  • Gomis González, Maria, 1988-
  • Chan, Li
  • Hiance-Delahaye, Anna
  • Dierssen, Mara
  • Strydom, Andre
  • Torre Fornell, Rafael de la
Introduction/background: Individuals with Down syndrome (DS) face a higher and earlier risk of overweight and/or obesity than the general population, influenced by factors like limited physical activity, suboptimal diet, stress, and sleep disorders. Despite the impact these lifestyle factors can have, there is a significant lack of robust, evidence-based guidelines for managing overweight and obesity in these individuals, particularly for the adult population. Results: Based on findings from an observational study across three European sites, within the EU Horizon-2020 GO-DS21 project, in this short communication, we highlight some key insights for developing effective prevention and management strategies for overweight and obesity in people with Down syndrome. Conclusions: In general terms, effective overweight and obesity management demands a holistic approach, integrating tailored diet and physical activity and actively addressing co-occurring health conditions. Moreover, the active participation of the family and peers is crucial for promoting sustainable healthy habits and for enhancing the overall quality of life of people with Down syndrome., This work (Gene overdosage and comorbidities during the early lifetime in Down syndrome project) was supported by the EU Horizon 2020 program (Grant agreement ID: 848077).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene

  • Ortega, Mireia
  • De Toma, Ilario
  • Fernández-Blanco, Álvaro
  • Calderón Moruno, Anna
  • Barahona, Lucía
  • Trullàs, Ramón
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Introduction: DYRK1A is a dual-specificity kinase that is overexpressed in Down syndrome (DS) and plays a key role in neurogenesis, neuronal differentiation and function, cognitive phenotypes, and aging. Dyrk1A has also been implicated in cerebellar abnormalities observed in association with DS, and normalization of Dyrk1A dosage rescues granular and Purkinje cell densities in a trisomic DS mouse model. However, the underlying molecular mechanisms governing these processes are unknown. Methods: To shed light on the effects of Dyrk1A overexpression in the cerebellum, here we investigated the cerebellar proteome in transgenic Dyrk1A overexpressing mice in basal conditions and after treatment with green tea extract containing epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor. Results and discussion: Our results showed that Dyrk1A overexpression alters oxidative phosphorylation and mitochondrial function in the cerebellum of transgenic mice. These alterations are significantly rescued upon EGCG-containing green tea extract treatment, suggesting that its effects in DS could depend in part on targeting mitochondria, as shown by the partially restoration by the treatment of the increased mtDNA copy number in TG non-treated mice., This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Framework Programme under grant agreement no 848077. This reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (grant number 2002), NIH Blueprint for Neuroscience Research (grant number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and EU Joint Programme—Neurodegenerative Disease Research (Heroes AC170006). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2023 update

  • Carriba, Paulina
  • Lorenzon, Nicola
  • Dierssen, Mara
Several advances in the field of neurodevelopmental diseases (NDDs) have been reported by 2022. Of course, NDDs comprise a diverse group of disorders, most of which with different aetiologies. However, owing to the development and consolidation of technological approaches, such as proteomics and RNA-sequencing, and to the improvement of brain organoids along with the introduction of artificial intelligence (AI) for biodata analysis, in 2022 new aetiological mechanisms for some NDDs have been proposed. Here, we present hints of some of these findings. For instance, centrioles regulate neuronal migration and could be behind the aetiology of periventricular heterotopia; also, the accumulation of misfolded proteins could explain the neurological effects in COVID-19 patients; and, autism spectrum disorders (ASD) could be the expression of altered cortical arealization. We also cover other interesting aspects as the description of a new NDD characterized by deregulation of genes involved in stress granule (SG) assemblies, or the description of a newly discovered neural progenitor that explains the different phenotypes of tumours and cortical tubers in tuberous sclerosis complex (TSC) disease; and how it is possible to decipher the aetiology of sudden unexplained death in childhood (SUDC) or improve the diagnosis of cortical malformations using formalin-fixed paraffin-embedded samples., The lab of M.D. is supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2022), the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 research and innovation programme under grant agreements nº 848077 (GO-DS21) and under grant agreement nº 899986 (ICOD). Horizon Europe (Horizon-Hlth-2021-StayHlth-01-Psych-STRATA). This reflects only the author's view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2022-12-30-31-32). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Beyond quiescent and active: Intermediate microglial transcriptomic states in a mouse model of down syndrome

  • Fernández Blanco, Álvaro
  • Sierra, Cesar
  • Tejido, Clara
  • Dierssen, Mara
Research on microglia in Down syndrome (DS) has shown that microglial activation, increased inflammatory gene expression, and oxidative stress occur at different ages in DS brains. However, most studies resulted in simplistic definitions of microglia as quiescent or active, ignoring potential intermediate states. Indeed, recent work on microglial cells in young DS brains indicated that those evolve through different intermediate activation phenotypes before reaching a fully activated state. Here we used single nucleus RNA sequencing, to examine how trisomy affects microglial states in the Ts65Dn mouse model of DS. Despite no substantial changes in the proportion of glial populations, differential expression analysis revealed cell type-specific gene expression changes, most notably in astroglia, microglia, and oligodendroglia. Focusing on microglia, we identified differential expression of genes associated with different microglial states, including disease-associated microglia (DAMs), activated response microglia (ARMs), and human Alzheimer's disease microglia (HAMs), in trisomic microglia. Furthermore, pseudotime analysis reveals a unique reactivity profile in Ts65Dn microglia, with fewer in a homeostatic state and more in an intermediate aberrantly reactive state than in euploid microglia. This comprehensive understanding of microglial transcriptional dynamics sheds light on potential pathogenetic mechanisms but also possible avenues for therapy for neurodevelopmental disorders., The lab of MD is recognized by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). This project has received funding from the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033; PID2022-141900OB-I00 INTO-DS), from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848077 and 899986, Jerôme Lejeune Foundation #2002, Fundació La Marató-TV3 (#2016/20-30), JPND Heroes Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1; and CPP2022-009659). The CIBER of Rare Diseases is an initiative of the ISCIII. C.S. received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya, and A.F.B. received an FPI-SO fellowship (PRE2018-084504).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Environmental enrichment induces epigenomic and genome organization changes relevant for cognition

  • Espeso Gil, Sergio, 1985-
  • Holik, Aliaksei Z.
  • Bonnin, Sarah
  • Jhanwar, Shalu, 1986-
  • Chandrasekaran, Sandhya
  • Pique Regi, Roger
  • Albaigès-Ràfols, Júlia
  • Maher, Michael
  • Permanyer, Jon
  • Irimia Martínez, Manuel
  • Friedländer, Marc R.
  • Pons Espinal, Meritxell, 1986-
  • Akbarian, Schahram
  • Dierssen, Mara
  • Maass, Philipp G.
  • Hor, Charlotte N.
  • Ossowski, Stephan
In early development, the environment triggers mnemonic epigenomic programs resulting in memory and learning experiences to confer cognitive phenotypes into adulthood. To uncover how environmental stimulation impacts the epigenome and genome organization, we used the paradigm of environmental enrichment (EE) in young mice constantly receiving novel stimulation. We profiled epigenome and chromatin architecture in whole cortex and sorted neurons by deep-sequencing techniques. Specifically, we studied chromatin accessibility, gene and protein regulation, and 3D genome conformation, combined with predicted enhancer and chromatin interactions. We identified increased chromatin accessibility, transcription factor binding including CTCF-mediated insulation, differential occupancy of H3K36me3 and H3K79me2, and changes in transcriptional programs required for neuronal development. EE stimuli led to local genome re-organization by inducing increased contacts between chromosomes 7 and 17 (inter-chromosomal). Our findings support the notion that EE-induced learning and memory processes are directly associated with the epigenome and genome organization., We acknowledge support of the Spanish Ministry of Economy and Competitiveness (SAF2011-26216), “Centro de Excelencia Severo Ochoa 2017-2021,” SEV-2016-0571, the CERCA Programme/Generalitat de Catalunya and Jerome Lejeune Foundation, Swiss National Science Foundation Fellowship (PBLAP3_136878) and Co-funded by Marie Curie Actions to CNH. Resources for analyses conducted by SE-G were partially supported by the U.S. National Institutes of Mental Health Funds R01MH104341 and R01MH117790 and by the Social Sciences and Humanities Research Council of Canada (NFRFE-2018-01305). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, Agencia Estatal de Investigaci n (PID2019-110755RB-I00/AEI / 10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation programme under grant agreement No 848077, Jerôme Lejeune Foundation, NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30). RP-R resources were supported by R01GM109215. We thank the support of the University of Tübingen for the Open Access Publication Funds contribution.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A novel way to use cross-validation to measure connectivity by machine learning allows epilepsy surgery outcome prediction

  • Ivankovic, Karla
  • Principe, Alessandro
  • Montoya Gálvez, Justo
  • Manubens-Gil, Linus, 1989-
  • Zucca, Riccardo
  • Villoslada, Pablo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
The rate of success of epilepsy surgery, ensuring seizure-freedom, is limited by the lack of epileptogenicity biomarkers. Previous evidence supports the critical role of functional connectivity during seizure generation to characterize the epileptogenic network (EN). However, EN dynamics is highly variable across patients, hindering the development of diagnostic biomarkers. Without relying on specific connectivity variables, we focused on a general hypothesis that the EN undergoes the greatest magnitude of connectivity change during seizure generation, compared to other brain networks. To test this hypothesis, we developed a novel method for quantifying connectivity change between network states and applied it to identify surgical resection areas. A network state was represented by random snapshots of connectivity within a defined time interval of an intracranial EEG recording. A binary classifier was applied to classify two network states. The classifier generalization performance estimated by cross-validation was employed as a continuous measure of connectivity change. The algorithm generated a network by iteratively adding nodes until the connectivity change magnitude decreased. The resulting network was compared to the surgical resection, and the overlap score was used to predict post-surgical outcomes. The framework was evaluated in a consecutive cohort of 21 patients with a post-surgical follow-up of minimum 3 years. The best overlap between connectivity change networks and resections was obtained at the transition from pre-seizure to seizure (surgical outcome prediction ROC-AUC=90.3 %). However, all patients except one were correctly classified when considering the most informative time intervals. Time intervals proportional to seizure length were more informative than the almost universally used fixed intervals. This study demonstrates that connectivity can be successfully classified with a machine learning analysis and provide information for distinguishing a separate epileptogenic functional network. In summary, the connectivity change analysis could accurately identify epileptogenic networks validated by surgery outcome classification. Connectivity change magnitude at seizure transition could potentially serve as an EN biomarker. The tool provided by this study may aid surgical decision-making., FLAG–ERA JTC 2017 Human Brain Project, CAUSALTOMICS (PCI2018–092860) (AP, KI). Fundación Tatiana - Proyectos en Neurociencia - Grant 2022–1514 (AP). Ajuts destinats a universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802) (KI). Emergent Cluster of the Human Brain (CECH) and the European Regional Development Fund (FEDER) 001-P-001682 (RZ). The lab of MD was supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). Agencia Estatal de Investigación (PID2019–110755RB-I00/AEI/10.13039/501100011033) (MD). The European Union's Horizon 2020 Research and Innovation Program under grant agreement No 848077 (MD). NIH (Grant Number: 1R01EB 028159–01) (MD). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Down syndrome is a metabolic disease: altered insulin signaling mediates peripheral and brain dysfunctions

  • Dierssen, Mara
  • Fructuoso, Marta
  • Martínez de Lagrán Cabredo, María
  • Perluigi, Marzia
  • Barone, Eugenio
Down syndrome (DS) is the most frequent chromosomal abnormality that causes intellectual disability, resulting from the presence of an extra complete or segment of chromosome 21 (HSA21). In addition, trisomy of HSA21 contributes to altered energy metabolism that appears to be a strong determinant in the development of pathological phenotypes associated with DS. Alterations include, among others, mitochondrial defects, increased oxidative stress levels, impaired glucose, and lipid metabolism, finally resulting in reduced energy production and cellular dysfunctions. These molecular defects seem to account for a high incidence of metabolic disorders, i.e., diabetes and/or obesity, as well as a higher risk of developing Alzheimer's disease (AD) in DS. A dysregulation of the insulin signaling with reduced downstream pathways represents a common pathophysiological aspect in the development of both peripheral and central alterations leading to diabetes/obesity and AD. This is further strengthened by evidence showing that the molecular mechanisms responsible for such alterations appear to be similar between peripheral organs and brain. Considering that DS subjects are at high risk to develop either peripheral or brain metabolic defects, this review will discuss current knowledge about the link between trisomy of HSA21 and defects of insulin and insulin-related pathways in DS. Drawing the molecular signature underlying these processes in DS is a key challenge to identify novel drug targets and set up new prevention strategies aimed to reduce the impact of metabolic disorders and cognitive decline., This work was supported by Fondi Ateneo grant funded by the Sapienza University n° RM11715C77336E99 to EB and n° C26H15JT9X to MP, Fondation Jérôme Lejeune (2019b – Project #1887) to EB; Fondation Jérôme Lejeune, MINECO (SAF2016-79956-R), H2020 SC1, GO-DS21- 848077, CDTI (“Smartfoods”), Fundació La Marató De TV3 (201620-31_MDierssen), and JPND HEROES (tHE cRossroad Of dEmentia Syndromes to MD). The CRG was a Center of Excellence Severo Ochoa SEV-2016-0571.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Social factors influence behavior in the novel object recognition task in a mouse model of down syndrome

  • Sierra, Cesar
  • De Toma, Ilario
  • Lo Cascio, Lorenzo
  • Vegas Lozano, Esteban
  • Dierssen, Mara
The use of mouse models has revolutionized the field of Down syndrome (DS), increasing our knowledge about neuropathology and helping to propose new therapies for cognitive impairment. However, concerns about the reproducibility of results in mice and their translatability to humans have become a major issue, and controlling for moderators of behavior is essential. Social and environmental factors, the experience of the researcher, and the sex and strain of the animals can all have effects on behavior, and their impact on DS mouse models has not been explored. Here we analyzed the influence of a number of social and environmental factors, usually not taken into consideration, on the behavior of male and female wild-type and trisomic mice (the Ts65Dn model) in one of the most used tests for proving drug effects on memory, the novel object recognition (NOR) test. Using principal component analysis and correlation matrices, we show that the ratio of trisomic mice in the cage, the experience of the experimenter, and the timing of the test have a differential impact on male and female and on wild-type and trisomic behavior. We conclude that although the NOR test is quite robust and less susceptible to environmental influences than expected, to obtain useful results, the phenotype expression must be contrasted against the influences of social and environmental factors.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Environmental Enrichment Induces Epigenomic and Genome Organization Changes Relevant for Cognition

  • Espeso Gil, Sergio
  • Holik, Aliaksei Z.
  • Bonnin, Sarah
  • Jhanwar, Shalu
  • Chandrasekaran, Sandhya
  • Pique Regi, Roger
  • Albaigès, Júlia
  • Maher, Michael
  • Permanyer, Jon
  • Irimia Martínez, Manuel
  • Friedländer, Marc R.
  • Pons Espinal, Meritxell
  • Akbarian, Schahram
  • Dierssen, Mara
  • Maass, Philipp
  • Hor, Charlotte N.
  • Ossowski, Stephan
In early development, the environment triggers mnemonic epigenomic programs resulting in memory and learning experiences to confer cognitive phenotypes into adulthood. To uncover how environmental stimulation impacts the epigenome and genome organization, we used the paradigm of environmental enrichment (EE) in young mice constantly receiving novel stimulation. We profiled epigenome and chromatin architecture in whole cortex and sorted neurons by deep-sequencing techniques. Specifically, we studied chromatin accessibility, gene and protein regulation, and 3D genome conformation, combined with predicted enhancer and chromatin interactions. We identified increased chromatin accessibility, transcription factor binding including CTCF-mediated insulation, differential occupancy of H3K36me3 and H3K79me2, and changes in transcriptional programs required for neuronal development. EE stimuli led to local genome re-organization by inducing increased contacts between chromosomes 7 and 17 (inter-chromosomal). Our findings support the notion that EE-induced learning and memory processes are directly associated with the epigenome and genome organization.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene

  • Ortega, Mireia
  • Toma, Ilario de
  • Fernández-Blanco, Álvaro
  • Calderón, Anna
  • Barahona, Lucía
  • Trullas, Ramón
  • Sabidó, Eduard
  • Dierssen, Mara
Introduction: DYRK1A is a dual-specificity kinase that is overexpressed in Down syndrome (DS) and plays a key role in neurogenesis, neuronal differentiation and function, cognitive phenotypes, and aging. Dyrk1A has also been implicated in cerebellar abnormalities observed in association with DS, and normalization of Dyrk1A dosage rescues granular and Purkinje cell densities in a trisomic DS mouse model. However, the underlying molecular mechanisms governing these processes are unknown. Methods: To shed light on the effects of Dyrk1A overexpression in the cerebellum, here we investigated the cerebellar proteome in transgenic Dyrk1A overexpressing mice in basal conditions and after treatment with green tea extract containing epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor. Results and Discussion: Our results showed that Dyrk1A overexpression alters oxidative phosphorylation and mitochondrial function in the cerebellum of transgenic mice. These alterations are significantly rescued upon EGCG-containing green tea extract treatment, suggesting that its effects in DS could depend in part on targeting mitochondria, as shown by the partially restoration by the treatment of the increased mtDNA copy number in TG non-treated mice., This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Framework Programme under grant agreement no 848077. This reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (grant number 2002), NIH Blueprint for Neuroscience Research (grant number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and EU Joint Programme—Neurodegenerative Disease Research (Heroes AC170006). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A highly conserved neuronal microexon in DAAM1 controls actin dynamics, RHOA/ROCK signaling, and memory formation

  • Poliński, Patryk
  • Miret Cuesta, Marta
  • Zamora-Moratalla, Alfonsa
  • Mantica, Federica
  • Cantero-Recasens, Gerard
  • Viana, Carlotta
  • Sabariego-Navarro, Miguel
  • Normanno, Davide
  • Iñiguez, Luis P.
  • Morenilla-Palao, Cruz
  • Ordoño, Patricia
  • Bonnal, Sophie
  • Ellis, Jonathan D.
  • Gómez-Riera, Raúl
  • Fanlo-Ucar, Hugo
  • Yap, Dominic S.
  • Martínez de Lagrán, María
  • Fernández Blanco, Álvaro
  • Rodríguez Marín, Cristina
  • Permanyer, Jon
  • Fölsz, Orsolya
  • Domínguez-Sala, Eduardo
  • Sierra, César
  • Legutko, Diana
  • Wojnacki, José
  • Musoles Lleo, Juan Luis
  • Cosma, María Pía
  • Muñoz, Francisco José
  • Blencowe, Benjamín J.
  • Herrera, Eloisa
  • Dierssen, Mara
  • Irimia, Manuel
Actin cytoskeleton dynamics is essential for proper nervous system development and function. A conserved set of neuronal-specific microexons influences multiple aspects of neurobiology; however, their roles in regulating the actin cytoskeleton are unknown. Here, we study a microexon in DAAM1, a formin-homology-2 (FH2) domain protein involved in actin reorganization. Microexon inclusion extends the linker region of the DAAM1 FH2 domain, altering actin polymerization. Genomic deletion of the microexon leads to neuritogenesis defects and increased calcium influx in differentiated neurons. Mice with this deletion exhibit postsynaptic defects, fewer immature dendritic spines, impaired long-term potentiation, and deficits in memory formation. These phenotypes are associated with increased RHOA/ROCK signaling, which regulates actin-cytoskeleton dynamics, and are partially rescued by treatment with a ROCK inhibitor. This study highlights the role of a conserved neuronal microexon in regulating actin dynamics and cognitive functioning., We thank Kyung-Min Noh for providing the mESC line, Miguel Valverde and Francisco Muñoz for their help and feedback with the calcium imaging experiments, and members of the Irimia and Dierssen groups for constant scientific discussion and feedback. We also thank the CRG Genomics, Protein Technologies, Tissue Engineering and Advanced Light Microscopy Units for the RNA sequencing, protein purification, blastocyst injection and microscopy services, respectively. The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERCCoG-LS2-101002275 to M.I.), Spanish Ministry of Science and Innovation (PID2020-115040GB-I00 to M.I., PID2022−141900OB-I00 to M.D., PID2020- 114080GB-I00 to M.P.C., PID2023-1497670B-I00 to F.J.M. and PID2022-138245NB-I00 to E.H), the European Union’s Horizon 2020 research and innovation program under grant agreements No 964342 to M.P.C., 721890 to P.P. and 848077 to A.Z.M., the National Institutes of Health (NIH) (1R01NS137222-01 to M.D.) and AGAUR grants from Secretaria d’Universitats i Recerca del Departament d’Empresa iConeixement de la Generalitat de Catalunya to M.I., M.D. and M.P.C.. CRG acknowledges support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. M.S.N. received an FPU fellowship (FPU19/04789) from Ministerio de Universidades. This research was in part supported by grants from the Simons Foundation and Canadian Institutes of Health Research to B.J.B., who also holds the University of Toronto Banbury Chair in Medical Research and the Canada Research Chair in RNA Biology and Genomics., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001049-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Astrocytopathy Is Associated with CA1 Synaptic Dysfunction in a Mouse Model of Down Syndrome

  • Fernández-Blanco, Álvaro
  • González-Arias, Candela
  • Sierra, César
  • Zamora-Moratalla, Alfonsa
  • Perea, Gertrudis
  • Dierssen, Mara
This article belongs to the Special Issue Cellular and Molecular Alterations in the Down Syndrome Brain: A Starting Point for the Design of Therapeutic Approaches., Brain pathophysiology in Down syndrome (DS), the most common genetic cause of intellectual disability, has traditionally been considered a consequence of neuronal dysfunction. However, although it is well documented that astrocytes play a critical role in brain homeostasis, synaptic regulation, and neuronal support, and their malfunction has been associated with the onset and progression of different neurological disorders, only a few studies have addressed whether astrocyte dysfunction can contribute to the DS pathophysiology. Astrocytes are increased in number and size, and show increased levels of expression of astroglial markers like S100β and GFAP. In this study, we detected a region-specific increase in astrocyte population in CA1 and, to a lesser extent, in the dentate gyrus. Single-nucleus transcriptomic profiling identified markers associated with reactive astroglia, synaptic transmission, and neuroinflammation in trisomic astrocytes. Functional analysis revealed abnormal Ca2+ oscillations in trisomic astrocytes and impaired astrocyte-to-neuron communication in CA1, the most affected subregion, leading to astrocyte-mediated excitatory synaptic depression. Our findings demonstrate that astrocytes play an active and critical role in the pathophysiology of DS, not only as reactive responders to neuronal injury but as key contributors to the disease process itself. This astrocytic dysfunction presents a region-specific distribution within the hippocampus, suggesting localized vulnerability and complex glial involvement in DS-related neuropathology., The lab of MD is supported by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS funded by MICIU/AEI/10.13039/501100011033/FEDER, UE). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848077). The publication is part of the grant PRE2018-084504, funded by MCIN/AEI/10.13039/501100011033 and by the FSE+ (AFB). Additionally, we have been supported by Fundació La Marató TV3 (201620-31 and 225619), and by PID2022-142617NB-I00 and PID2019-106579RB-I00 funded by MCIN/AEI/10.13039/501100011033 to G.P., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Understanding obesity in Individuals with Down syndrome: caregiver perceptions, awareness, and motivation

  • Cahill, Thomas
  • Nalesso, Valerie
  • Clarke, Pat
  • Martínez de Lagran, María
  • Strydom, André
  • Chan, Li
  • Potier, Marie-Claude
  • Beckers, Johannes
  • Langohr, Klaus|||0000-0001-7075-9192
  • Lio, Pietro
  • De la Torre Fornell, Rafael
  • Forcano, Laura
  • Hiance Delahaye, Anne
  • Herault, Yann
  • Dierssen, Mara
  • Consortium, GO-DS21
Background: Individuals with Down syndrome (DS) are at an increased risk of obesity and, subsequently, its cardiometabolic and cognitive impacts. Caregivers play a critical role in managing health, yet their perceptions and behaviors have been poorly characterized. Methods: We performed a cross-sectional online survey of caregivers (n = 764) taking care of 48% females and 52% males with DS, conducted across European populations, predominantly in Spain and France. We assessed perceived obesity, perceived harmful- ness of current weight, professional consultation, and confidence in promoting healthy behaviors. Associations were examined using chi-square tests, correlation analysis, and ordinal and logistic regression models. Results: Around one-third (32%) of caregivers perceived their family member with DS with obesity. Perceived obesity changed with age and was more frequently reported in female family members with DS. Awareness of general metabolic risk factors was high among caregivers, but half of respondents were unaware that abdominal fat affects brain health. Consultation with healthcare professionals was uncommon (57% “Never/Rarely/Sometimes”) even among those perceived with obesity. Conclusions: Caregivers demonstrate good general awareness about high energy food risks but limited knowledge of the link between obesity and brain health. Enhancing caregiver education and supporting behavioral change could promote healthier lifestyles in families with individuals with DS., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rethinking intellectual disability from neuro- to astro-pathology

  • Fernández-Blanco, Álvaro
  • Dierssen, Mara
Neurodevelopmental disorders arise from genetic and/or from environmental factors and are characterized by different degrees of intellectual disability. The mechanisms that govern important processes sustaining learning and memory, which are severely affected in intellectual disability, have classically been thought to be exclusively under neuronal control. However, this vision has recently evolved into a more integrative conception in which astroglia, rather than just acting as metabolic supply and structural anchoring for neurons, interact at distinct levels modulating neuronal communication and possibly also cognitive processes. Recently, genetic tools have made it possible to specifically manipulate astrocyte activity unraveling novel functions that involve astrocytes in memory function in the healthy brain. However, astrocyte manipulation has also underscored potential mechanisms by which dysfunctional astrocytes could contribute to memory deficits in several neurodevelopmental disorders revealing new pathogenic mechanisms in intellectual disability. Here, we review the current knowledge about astrocyte dysfunction that might contribute to learning and memory impairment in neurodevelopmental disorders, with special focus on Fragile X syndrome and Down syndrome., Funding: The lab of MD is supported by the CRG Severo Ochoa excellence grant, the CIBER of Rare Diseases and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21- 848077, Jerôme Lejeune Foundation, NIH (Grant Number: 1R01EB 028159-01), Marató TV3, JPND Heroes project, and the Spanish Ministry of Science and Innovation (MICINN) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Environmental Enrichment Induces Epigenomic and Genome Organization Changes Relevant for Cognition

  • Espeso Gil, Sergio
  • Holik, Aliaksei Z.
  • Bonnin, Sarah
  • Jhanwar, Shalu
  • Chandrasekaran, Sandhya
  • Pique Regi, Roger
  • Albaigès, Júlia
  • Maher, Michael
  • Permanyer, Jon
  • Irimia Martínez, Manuel
  • Friedländer, Marc R.
  • Pons Espinal, Meritxell
  • Akbarian, Schahram
  • Dierssen, Mara
  • Maass, Philipp
  • Hor, Charlotte N.
  • Ossowski, Stephan
In early development, the environment triggers mnemonic epigenomic programs resulting in memory and learning experiences to confer cognitive phenotypes into adulthood. To uncover how environmental stimulation impacts the epigenome and genome organization, we used the paradigm of environmental enrichment (EE) in young mice constantly receiving novel stimulation. We profiled epigenome and chromatin architecture in whole cortex and sorted neurons by deep-sequencing techniques. Specifically, we studied chromatin accessibility, gene and protein regulation, and 3D genome conformation, combined with predicted enhancer and chromatin interactions. We identified increased chromatin accessibility, transcription factor binding including CTCF-mediated insulation, differential occupancy of H3K36me3 and H3K79me2, and changes in transcriptional programs required for neuronal development. EE stimuli led to local genome re-organization by inducing increased contacts between chromosomes 7 and 17 (inter-chromosomal). Our findings support the notion that EE-induced learning and memory processes are directly associated with the epigenome and genome organization.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A highly conserved neuronal microexon in DAAM1 controls actin dynamics, RHOA/ROCK signaling, and memory formation

  • Poliński, Patryk
  • Miret-Cuesta, Marta
  • Zamora Moratalla, Alfonsa
  • Mantica, Federica
  • Cantero Recasens, Gerard, 1984-
  • Viana, Carlotta
  • Sabariego Navarro, Miguel
  • Normanno, Davide
  • Iñiguez, Luis P.
  • Bonnal, Sophie
  • Gómez-Riera, Raúl
  • Fanlo-Ucar, Hugo
  • Yap, Dominic S.
  • Martínez de Lagrán Cabredo, María
  • Fernández-Blanco, Álvaro
  • Rodríguez-Marin, Cristina
  • Permanyer, Jon
  • Fölsz, Orsolya
  • Domínguez-Sala, Eduardo
  • Sierra, Cesar
  • Wojnacki, José
  • Musoles Lleo, Juan Luis
  • Cosma, Maria Pia
  • Muñoz López, Francisco José, 1964-
  • Dierssen, Mara
  • Irimia Martínez, Manuel
Actin cytoskeleton dynamics is essential for proper nervous system development and function. A conserved set of neuronal-specific microexons influences multiple aspects of neurobiology; however, their roles in regulating the actin cytoskeleton are unknown. Here, we study a microexon in DAAM1, a formin-homology-2 (FH2) domain protein involved in actin reorganization. Microexon inclusion extends the linker region of the DAAM1 FH2 domain, altering actin polymerization. Genomic deletion of the microexon leads to neuritogenesis defects and increased calcium influx in differentiated neurons. Mice with this deletion exhibit postsynaptic defects, fewer immature dendritic spines, impaired long-term potentiation, and deficits in memory formation. These phenotypes are associated with increased RHOA/ROCK signaling, which regulates actin-cytoskeleton dynamics, and are partially rescued by treatment with a ROCK inhibitor. This study highlights the role of a conserved neuronal microexon in regulating actin dynamics and cognitive functioning., The research has been funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (ERCCoG-LS2-101002275 to M.I.), Spanish Ministry of Science and Innovation (PID2020-115040GB-I00 to M.I., PID2022−141900OB-I00 to M.D., PID2020- 114080GB-I00 to M.P.C., PID2023-1497670B-I00 to F.J.M. and PID2022-138245NB-I00 to E.H), the European Union’s Horizon 2020 research and innovation program under grant agreements No 964342 to M.P.C., 721890 to P.P. and 848077 to A.Z.M., the National Institutes of Health (NIH) (1R01NS137222-01 to M.D.) and AGAUR grants from Secretaria d’Universitats i Recerca del Departament d’Empresa iConeixement de la Generalitat de Catalunya to M.I., M.D. and M.P.C.. CRG acknowledges support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. M.S.N. received an FPU fellowship (FPU19/04789) from Ministerio de Universidades. This research was in part supported by grants from the Simons Foundation and Canadian Institutes of Health Research to B.J.B., who also holds the University of Toronto Banbury Chair in Medical Research and the Canada Research Chair in RNA Biology and Genomics.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Social factors influence behavior in the novel object recognition task in a mouse model of down syndrome

  • Sierra, Cesar
  • De Toma, Ilario
  • Lo Cascio, Lorenzo
  • Vegas, Esteban
  • Dierssen, Mara
The use of mouse models has revolutionized the field of Down syndrome (DS), increasing our knowledge about neuropathology and helping to propose new therapies for cognitive impairment. However, concerns about the reproducibility of results in mice and their translatability to humans have become a major issue, and controlling for moderators of behavior is essential. Social and environmental factors, the experience of the researcher, and the sex and strain of the animals can all have effects on behavior, and their impact on DS mouse models has not been explored. Here we analyzed the influence of a number of social and environmental factors, usually not taken into consideration, on the behavior of male and female wild-type and trisomic mice (the Ts65Dn model) in one of the most used tests for proving drug effects on memory, the novel object recognition (NOR) test. Using principal component analysis and correlation matrices, we show that the ratio of trisomic mice in the cage, the experience of the experimenter, and the timing of the test have a differential impact on male and female and on wild-type and trisomic behavior. We conclude that although the NOR test is quite robust and less susceptible to environmental influences than expected, to obtain useful results, the phenotype expression must be contrasted against the influences of social and environmental factors., The lab of MD is supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 848077. Jerôme Lejeune Foundation (Grant number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and JPND (Heroes; AC17/00006). The Centre for Genomic Regulation (CRG) acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII. CS received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Social factors influence behavior in the novel object recognition task in a mouse model of down syndrome

  • Sierra, Cesar
  • De Toma, Ilario
  • Lo Cascio, Lorenzo
  • Vegas Lozano, Esteban
  • Dierssen, Mara
The use of mouse models has revolutionized the field of Down syndrome (DS), increasing our knowledge about neuropathology and helping to propose new therapies for cognitive impairment. However, concerns about the reproducibility of results in mice and their translatability to humans have become a major issue, and controlling for moderators of behavior is essential. Social and environmental factors, the experience of the researcher, and the sex and strain of the animals can all have effects on behavior, and their impact on DS mouse models has not been explored. Here we analyzed the influence of a number of social and environmental factors, usually not taken into consideration, on the behavior of male and female wild-type and trisomic mice (the Ts65Dn model) in one of the most used tests for proving drug effects on memory, the novel object recognition (NOR) test. Using principal component analysis and correlation matrices, we show that the ratio of trisomic mice in the cage, the experience of the experimenter, and the timing of the test have a differential impact on male and female and on wild-type and trisomic behavior. We conclude that although the NOR test is quite robust and less susceptible to environmental influences than expected, to obtain useful results, the phenotype expression must be contrasted against the influences of social and environmental factors.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Differences in clinical presentation, severity, and treatment of COVID-19 among individuals with Down syndrome from India and high-income countries: Data from the Trisomy 21 Research Society survey

  • Pinku, Halder
  • Hüls, Anke
  • Feany, Patrick T.
  • Baumer, Nicole
  • Dierssen, Mara
  • Bargagna, Stefania
  • Costa, Alberto C.S.
  • Chicoine, Brian Allen
  • Rebillat, Anne-Sophie
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Rohrer, R. Tilman
  • Levin, Johannes
  • Lakhanpaul, Monica
  • Carfì, Angelo
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Ghosh, Sujay
  • Trisomy Research Society Covid-Initiative Study Group
Background: People with Down syndrome (DS) are one of the highest risk groups for mortality associated with COVID-19, but outcomes may differ across countries due to different co-morbidity profiles, exposures, and societal practices, which could have implications for disease management. This study is designed to identify differences in clinical presentation, severity, and treatment of COVID-19 between India and several high-income countries (HICs). Methods: We used data from an international survey to examine the differences in disease manifestation and management for COVID-19 patients with DS from India vs HIC. De-identified survey data collected from April 2020 to August 2021 were analysed. Results: COVID-19 patients with DS from India were on average nine years younger than those from HICs. Comorbidities associated with a higher risk for severe COVID-19 were more frequent among the patients from India than from HICs. Hospitalizations were more frequent among patients from India as were COVID-19-related medical complications. Treatment strategies differed between India and HICs, with more frequent use of antibiotics in India. The average severity score of 3.31 was recorded for Indian DS in contrast to 2.3 for European and 2.04 for US cases. Conclusions: Presentation and outcomes of COVID-19 among individuals with DS were more severe for patients from India than for those from HIC. Global efforts should especially target vaccination campaigns and other risk-reducing interventions for individuals with DS from low-income countries., PH is supported by University Grant Commission, India (UGC/21/06/2015 (i)EU-V). SG is supported by Government of West Bengal (DST, WB) Grant No. SG/WBDST/S&T 1000114/2016 and UGC-UPEII, DST-PURSE programs (Grant No. UGC/859/UPE-2 BIO). AH is supported by the HERCULES Center (NIEHS P30ES019776) and the LuMind IDSC Foundation. The REDCap survey and database management system at Emory University was supported by Library Information Technology Services grant support (UL1 TR000424). ACSC is supported by the Alana USA Foundation, Awakening Angels Foundation, and the Infectious Diseases Society of America (IDSA). MD is supported by the Centre for Genomic Regulation Severo Ochoa excellence grant, the CIBER of Rare Diseases, DURSI 2017SGR595, and acknowledges the Spanish Ministry of Science, Innovation and Universities (MSIU) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and CERCA (GenCat). AS is supported by the MRC (MR/ S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The LeJeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down syndrome GO-DS21- 848077). ML was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust). DRdeA was partially supported by Spanish Fondo de Investigacion Sanitaria-Instituto Carlos III (FIS-ISCIII), grant No. PI19/00634; BAC has research support from Various Grateful Families of Patients. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/ 0014). The DCEXS is a ‘Unidad de Excelencia Marí a de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agencia de G d ’AjutsUniversitarisi de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). This study was also supported by the Fondo de InvestigacionesSanitario (FIS), Instituto de Salud Carlos III (PI18/00335 to MCI, PI14/ 01126 and PI17/01019 to JF), partly jointly funded by Fondo Europeo de Desarrollo Regional, Union Europea, Una manera de hacer Europa; the Jerome Lejeune Foundation (No.1319 Cycle 2019B to MCI); the National Institutes of Health (NIA grants 1R01AG056850 – 01A1; R21AG056974 and R01AG061566 to JF); Departament de Salut de la Generalitat de Catalunya, PlaEstrategic de RecercaiInnovaci o enSalut (SLT006/17/00119 to JF); and Fundacio La Marat o de TV3 (20141210 to JF).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Down syndrome is a metabolic disease: altered insulin signaling mediates peripheral and brain dysfunctions

  • Dierssen, Mara
  • Fructuoso, Marta
  • Martínez de Lagrán Cabredo, María
  • Perluigi, Marzia
  • Barone, Eugenio
Down syndrome (DS) is the most frequent chromosomal abnormality that causes intellectual disability, resulting from the presence of an extra complete or segment of chromosome 21 (HSA21). In addition, trisomy of HSA21 contributes to altered energy metabolism that appears to be a strong determinant in the development of pathological phenotypes associated with DS. Alterations include, among others, mitochondrial defects, increased oxidative stress levels, impaired glucose, and lipid metabolism, finally resulting in reduced energy production and cellular dysfunctions. These molecular defects seem to account for a high incidence of metabolic disorders, i.e., diabetes and/or obesity, as well as a higher risk of developing Alzheimer's disease (AD) in DS. A dysregulation of the insulin signaling with reduced downstream pathways represents a common pathophysiological aspect in the development of both peripheral and central alterations leading to diabetes/obesity and AD. This is further strengthened by evidence showing that the molecular mechanisms responsible for such alterations appear to be similar between peripheral organs and brain. Considering that DS subjects are at high risk to develop either peripheral or brain metabolic defects, this review will discuss current knowledge about the link between trisomy of HSA21 and defects of insulin and insulin-related pathways in DS. Drawing the molecular signature underlying these processes in DS is a key challenge to identify novel drug targets and set up new prevention strategies aimed to reduce the impact of metabolic disorders and cognitive decline., This work was supported by Fondi Ateneo grant funded by the Sapienza University n° RM11715C77336E99 to EB and n° C26H15JT9X to MP, Fondation Jérôme Lejeune (2019b – Project #1887) to EB; Fondation Jérôme Lejeune, MINECO (SAF2016-79956-R), H2020 SC1, GO-DS21- 848077, CDTI (“Smartfoods”), Fundació La Marató De TV3 (201620-31_MDierssen), and JPND HEROES (tHE cRossroad Of dEmentia Syndromes to MD). The CRG was a Center of Excellence Severo Ochoa SEV-2016-0571.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2024 update

  • Martínez de Lagrán Cabredo, María
  • Bascón-Cardozo, Karen
  • Dierssen, Mara
Neurodevelopmental disorders encompass a range of conditions such as intellectual disability, autism spectrum disorder, rare genetic disorders and developmental and epileptic encephalopathies, all manifesting during childhood. Over 1,500 genes involved in various signaling pathways, including numerous transcriptional regulators, spliceosome elements, chromatin-modifying complexes and de novo variants have been recognized for their substantial role in these disorders. Along with new machine learning tools applied to neuroimaging, these discoveries facilitate genetic diagnoses, providing critical insights into neuropathological mechanisms and aiding in prognosis, and precision medicine. Also, new findings underscore the importance of understanding genetic contributions beyond protein-coding genes and emphasize the role of RNA and non-coding DNA molecules but also new players, such as transposable elements, whose dysregulation generates gene function disruption, epigenetic alteration, and genomic instability. Finally, recent developments in analyzing neuroimaging now offer the possibility of characterizing neuronal cytoarchitecture in vivo, presenting a viable alternative to traditional post-mortem studies. With a recently launched digital atlas of human fetal brain development, these new approaches will allow answering complex biological questions about fetal origins of cognitive function in childhood. In this review, we present ten fascinating topics where major progress has been made in the last year., The lab of M.D. acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome

  • Martínez de Lagrán Cabredo, María
  • Elizalde-Torrent, Aleix
  • Paredes, Roger
  • Clotet, Bonaventura
  • Dierssen, Mara
An elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases. Down syndrome (DS) is the most common genetic disorder associated with intellectual disability and a genetic form of Alzheimer's disease. For this reason, we hypothesized that treatment with reverse transcriptase inhibitors could ameliorate DS phenotypes. In this proof of concept study, we treated trisomic (Ts65Dn) mice, a model of DS, with lamivudine, a reverse transcriptase inhibitor. We detected a significant improvement of neurobehavioural phenotypes, and a complete rescue of the hippocampal-dependent recognition memory upon treatment with lamivudine. Despite clinical studies in patients with DS are warranted, this study lays the groundwork for a novel and actionable therapeutic approach., Agencia Estatal de Investigación. Grant Number: PID2019-110755RB-I00/AEI/10.13039/501100011033. Horizon 2020 Framework Programme. Grant Number: 848077
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Meta-analysis of transcriptomic data reveals clusters of consistently deregulated gene and disease ontologies in Down syndrome

  • De Toma, Ilario
  • Sierra, Cesar
  • Dierssen, Mara
Trisomy of human chromosome 21 (HSA21) causes Down syndrome (DS). The trisomy does not simply result in the upregulation of HSA21--encoded genes but also leads to a genome-wide transcriptomic deregulation, which affect differently each tissue and cell type as a result of epigenetic mechanisms and protein-protein interactions. We performed a meta-analysis integrating the differential expression (DE) analyses of all publicly available transcriptomic datasets, both in human and mouse, comparing trisomic and euploid transcriptomes from different sources. We integrated all these data in a "DS network". We found that genome wide deregulation as a consequence of trisomy 21 is not arbitrary, but involves deregulation of specific molecular cascades in which both HSA21 genes and HSA21 interactors are more consistently deregulated compared to other genes. In fact, gene deregulation happens in "clusters", so that groups from 2 to 13 genes are found consistently deregulated. Most of these events of "co-deregulation" involve genes belonging to the same GO category, and genes associated with the same disease class. The most consistent changes are enriched in interferon related categories and neutrophil activation, reinforcing the concept that DS is an inflammatory disease. Our results also suggest that the impact of the trisomy might diverge in each tissue due to the different gene set deregulation, even though the triplicated genes are the same. Our original method to integrate transcriptomic data confirmed not only the importance of known genes, such as SOD1, but also detected new ones that could be extremely useful for generating or confirming hypotheses and supporting new putative therapeutic candidates. We created "metaDEA" an R package that uses our method to integrate every kind of transcriptomic data and therefore could be used with other complex disorders, such as cancer. We also created a user-friendly web application to query Ensembl gene IDs and retrieve all the information of their differential expression across the datasets., Funding: The lab of MD is supported by the Departament d'Universitats, Recerca i Societat de la Informació (DURSI) de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We acknowledge the support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/ 10.13039/501100011033), H2020 SC1 (GO-DS21- 848077), Jerôme Lejeune Foundation (#2002), NIH (#1R01EB 028159-01), Fundació La Marató-TV3 (#2016/20-30), JPND Heroes AC170006 Ministerio de Ciencia Innovación y Universidades (#RTC2019-007230-1 and #RTC2019-007329-1). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

COVID-19 in children with down syndrome: data from the trisomy 21 Research Society Survey

  • Emes, David
  • Hüls, Anke
  • Baumer, Nicole
  • Dierssen, Mara
  • Puri, Shiela
  • Russell, Lauren
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Bargagna, Stefania
  • Brandão, Ana Cláudia
  • Costa, Alberto C.S.
  • Feany, Patrick T.
  • Chicoine, Brian Allen
  • Ghosh, Sujay
  • Rebillat, Anne-Sophie
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Roher, Tilman R.
  • Levin, Johannes
  • Lakhanpaul, Monica
  • Trisomy Research Society Covid-Initiative Study Group
Adults with Down Syndrome (DS) are at higher risk for severe outcomes of coronavirus disease 2019 (COVID-19) than the general population, but evidence is required to understand the risks for children with DS, which is necessary to inform COVID-19 shielding advice and vaccination priorities. We aimed to determine the epidemiological and clinical characteristics of COVID-19 in children with DS. Using data from an international survey obtained from a range of countries and control data from the United States, we compared the prevalence of symptoms and medical complications and risk factors for severe outcomes between DS and non-DS paediatric populations with COVID-19. Hospitalised COVID-19 patients <18 years with DS had a higher incidence of respiratory symptoms, fever, and several medical complications from COVID-19 than control patients without DS <18 years. Older age, obesity, and epilepsy were significant risk factors for hospitalisation among paediatric COVID-19 patients with DS, and age and thyroid disorder were significant risk factors for acute respiratory distress syndrome. Mortality rates were low in all paediatric COVID-19 patients (with and without DS), contrasting with previous findings in adults with DS (who exhibit higher mortality than those without DS). Children with DS are at increased risk for more severe presentations of COVID-19. Efforts should be made to ensure the comprehensive and early detection of COVID-19 in this population and to identify children with DS who present comorbidities that pose a risk for a severe course of COVID-19. Our results emphasize the importance of vaccinating children with DS as soon as they become eligible., This work is supported by grants from the following bodies: Down Syndrome Affiliates in Action, Down Syndrome Medical Interest Group-USA, GiGi’s Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, National Down Syndrome Society, National Task Group on Intellectual Disabilities and Dementia Practices. AH is supported by the HERCULES Center (NIEHS P30ES019776). The REDCap survey and database management system at Emory University was supported by Library Information Technology Services grant support (UL1 TR000424). MD is supported by the Centre for Genomic Regulation Severo Ochoa excellence grant, the CIBER of Rare Diseases, and DURSI 2017SGR595, and acknowledges the Spanish Ministry of Science, Innovation and Universities (MSIU) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and CERCA (GenCat). AS is supported by the MRC (MR/S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The LeJeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21- 848077). ML was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at UCL Great Ormond Street Institute of Child Health/Great Ormond Street Hospital NHS Foundation Trust). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). This study was also supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI18/00335 to MCI, PI14/01126 and PI17/01019 to JF), partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa; the Jérôme Lejeune Foundation (No. 1319 Cycle 2019B to MCI); the National Institutes of Health (NIA grants 1R01AG056850 - 01A1; R21AG056974 and R01AG061566 to JF); Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (SLT006/17/00119 to JF); and Fundació La Marató de TV3 (20141210 to JF)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Environmental enrichment induces epigenomic and genome organization changes relevant for cognition

  • Espeso Gil, Sergio, 1985-
  • Holik, Aliaksei Z.
  • Bonnin, Sarah
  • Jhanwar, Shalu, 1986-
  • Chandrasekaran, Sandhya
  • Pique Regi, Roger
  • Albaigès-Ràfols, Júlia
  • Maher, Michael
  • Permanyer, Jon
  • Irimia Martínez, Manuel
  • Friedländer, Marc R.
  • Pons Espinal, Meritxell, 1986-
  • Akbarian, Schahram
  • Dierssen, Mara
  • Maass, Philipp G.
  • Hor, Charlotte N.
  • Ossowski, Stephan
In early development, the environment triggers mnemonic epigenomic programs resulting in memory and learning experiences to confer cognitive phenotypes into adulthood. To uncover how environmental stimulation impacts the epigenome and genome organization, we used the paradigm of environmental enrichment (EE) in young mice constantly receiving novel stimulation. We profiled epigenome and chromatin architecture in whole cortex and sorted neurons by deep-sequencing techniques. Specifically, we studied chromatin accessibility, gene and protein regulation, and 3D genome conformation, combined with predicted enhancer and chromatin interactions. We identified increased chromatin accessibility, transcription factor binding including CTCF-mediated insulation, differential occupancy of H3K36me3 and H3K79me2, and changes in transcriptional programs required for neuronal development. EE stimuli led to local genome re-organization by inducing increased contacts between chromosomes 7 and 17 (inter-chromosomal). Our findings support the notion that EE-induced learning and memory processes are directly associated with the epigenome and genome organization., We acknowledge support of the Spanish Ministry of Economy and Competitiveness (SAF2011-26216), “Centro de Excelencia Severo Ochoa 2017-2021,” SEV-2016-0571, the CERCA Programme/Generalitat de Catalunya and Jerome Lejeune Foundation, Swiss National Science Foundation Fellowship (PBLAP3_136878) and Co-funded by Marie Curie Actions to CNH. Resources for analyses conducted by SE-G were partially supported by the U.S. National Institutes of Mental Health Funds R01MH104341 and R01MH117790 and by the Social Sciences and Humanities Research Council of Canada (NFRFE-2018-01305). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, Agencia Estatal de Investigaci n (PID2019-110755RB-I00/AEI / 10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation programme under grant agreement No 848077, Jerôme Lejeune Foundation, NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30). RP-R resources were supported by R01GM109215. We thank the support of the University of Tübingen for the Open Access Publication Funds contribution.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Re-establishment of the epigenetic state and rescue of kinome deregulation in Ts65Dn mice upon treatment with green tea extract and environmental enrichment

  • De Toma, Ilario
  • Ortega, M.
  • Catuara Solarz, Silvina, 1986-
  • Sierra, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Down syndrome (DS) is the main genetic cause of intellectual disability due to triplication of human chromosome 21 (HSA21). Although there is no treatment for intellectual disability, environmental enrichment (EE) and the administration of green tea extracts containing epigallocatechin-3-gallate (EGCG) improve cognition in mouse models and individuals with DS. Using proteome, and phosphoproteome analysis in the hippocampi of a DS mouse model (Ts65Dn), we investigated the possible mechanisms underlying the effects of green tea extracts, EE and their combination. Our results revealed disturbances in cognitive-related (synaptic proteins, neuronal projection, neuron development, microtubule), GTPase/kinase activity and chromatin proteins. Green tea extracts, EE, and their combination restored more than 70% of the phosphoprotein deregulation in Ts65Dn, and induced possible compensatory effects. Our downstream analyses indicate that re-establishment of a proper epigenetic state and rescue of the kinome deregulation may contribute to the cognitive rescue induced by green tea extracts., This work was supported by the Fondation Jérôme Lejeune Foundation (Project #1347 “Elucidation of the mechanism of action of epigallocatechin-3-gallate as a therapeutic agent on the cognitive phenotype in Down Syndrome mice models”), Agencia Estatal de Investigación (AEI) (PID2019-110755RB-I00/AEI/10.13039/501100011033), H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21-848077, Fundació La Marató De TV3 (201620-31_MDierssen), EU (JPND HEROES (tHE cRossroad Of dEmentia Syndromes), NIH (Grant Number: 1R01EB 028159-01). The CRG is a Center of Excellence Severo Ochoa. The CIBER of Rare Diseases is an initiative of the ISCIII. The laboratories of M. Dierssen and E. Sabidó are supported by DIUE de la Generalitat de Catalunya (Grups consolidats 2017SGR926, 2017SGR595). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neurodevelopmental disorders: 2023 update

  • Carriba, Paulina
  • Lorenzon, Nicola
  • Dierssen, Mara
Several advances in the field of neurodevelopmental diseases (NDDs) have been reported by 2022. Of course, NDDs comprise a diverse group of disorders, most of which with different aetiologies. However, owing to the development and consolidation of technological approaches, such as proteomics and RNA-sequencing, and to the improvement of brain organoids along with the introduction of artificial intelligence (AI) for biodata analysis, in 2022 new aetiological mechanisms for some NDDs have been proposed. Here, we present hints of some of these findings. For instance, centrioles regulate neuronal migration and could be behind the aetiology of periventricular heterotopia; also, the accumulation of misfolded proteins could explain the neurological effects in COVID-19 patients; and, autism spectrum disorders (ASD) could be the expression of altered cortical arealization. We also cover other interesting aspects as the description of a new NDD characterized by deregulation of genes involved in stress granule (SG) assemblies, or the description of a newly discovered neural progenitor that explains the different phenotypes of tumours and cortical tubers in tuberous sclerosis complex (TSC) disease; and how it is possible to decipher the aetiology of sudden unexplained death in childhood (SUDC) or improve the diagnosis of cortical malformations using formalin-fixed paraffin-embedded samples., The lab of M.D. is supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2022), the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 research and innovation programme under grant agreements nº 848077 (GO-DS21) and under grant agreement nº 899986 (ICOD). Horizon Europe (Horizon-Hlth-2021-StayHlth-01-Psych-STRATA). This reflects only the author's view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2022-12-30-31-32). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

COVID-19 vaccination of individuals with Down syndrome-data from the trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to be Vaccinated

  • Hüls, Anke
  • Dierssen, Mara
  • Strydom, Andre
Individuals with Down syndrome (DS) are among the groups with the highest risk for severe COVID-19. Better understanding of the efficacy and risks of COVID-19 vaccines for individuals with DS may help improve uptake of vaccination. The T21RS COVID-19 Initiative launched an international survey to obtain information on safety and efficacy of COVID-19 vaccines for individuals with DS. De-identified survey data collected between March and December 2021 were analyzed. Of 2172 individuals with DS, 1973 (91%) had received at least one vaccine dose (57% BNT162b2), 107 (5%) were unvaccinated by choice, and 92 (4%) were unvaccinated for other reasons. Most participants had either no side effects (54%) or mild ones such as pain at the injection site (29%), fatigue (12%), and fever (7%). Severe side effects occurred in <0.5% of participants. About 1% of the vaccinated individuals with DS contracted COVID-19 after vaccination, and all recovered. Individuals with DS who were unvaccinated by choice were more likely to be younger, previously recovered from COVID-19, and also unvaccinated against other recommended vaccines. COVID-19 vaccines have been shown to be safe for individuals with DS and effective in terms of resulting in minimal breakthrough infections and milder disease outcomes among fully vaccinated individuals with DS., This work is supported by grants from: Down Syndrome Affiliates in Action, Down Syndrome Medical Interest Group-USA, GiGi’s Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, National Down Syndrome Society, National Task Group on Intellectual Disabilities and Dementia Practices. AH is supported by the HERCULES Center (NIEHS P30ES019776). AH and PTF are supported by the LuMind IDSC Foundation. The REDCap survey and database management system at Emory University was supported by Library Information Technology Services grant support (UL1 TR000424). MD is supported by the Centre for Genomic Regulation Severo Ochoa excellence grant, the CIBER of Rare Diseases, DURSI 2017SGR595, and acknowledges support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the Spanish Ministry of Science, Innovation and Universities (MSIU) to the EMBL partnership, the Centro de Excelencia Severo Ochoa and CERCA (GenCat). AS is supported by the MRC (MR/S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The Lejeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21-848077). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). DRA was supported by the Fondo de Investigaciones Sanitarias (grant PI19/00634, from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional Development Fund (ERDF) “A way to make Europe”) and the Fondation Jérôme Lejeune (grant no. 2021a-2069)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Methods for identifying epilepsy surgery targets using invasive EEG: a systematic review

  • Ivankovic, Karla
  • Principe, Alessandro
  • Zucca, Riccardo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
Background: The pre-surgical evaluation for drug-resistant epilepsy achieves seizure freedom in only 50-60% of patients. Efforts to identify quantitative intracranial EEG (qEEG) biomarkers of epileptogenicity are needed. This review summarizes and evaluates the design of qEEG studies, discusses barriers to biomarker adoption, and proposes refinements of qEEG study protocols. Methods: We included exploratory and prediction prognostic studies from MEDLINE and Scopus published between 2017 and 2023 that investigated qEEG markers for identifying the epileptogenic network as the surgical target. Cohort parameters, ground truth references, and analytical approaches were extracted. Results: Out of 1789 search results, 128 studies were included. The study designs were highly heterogeneous. Half of the studies included a non-consecutive cohort, with sample sizes ranging from 2 to 166 patients (median of 16). The most common minimum follow-up was one year, and the seizure onset zone was the most common ground truth. Prediction studies were heterogeneous in their analytical approaches, and only 25 studies validated the marker through post-surgical outcome prediction. Outcome prediction performance decreased in larger cohorts. Conversely, longer follow-up periods correlated with higher prediction accuracy, and connectivity-based approaches yielded better predictions. The data and code were available in only 9% of studies. Conclusions: To enhance the validation qEEG markers, we propose standardizing study designs to resemble clinical trials. This includes using a consecutive cohort with long-term follow-up, validating against surgical resection as ground truth, and evaluating markers through post-surgical outcome prediction. These considerations would improve the reliability and clinical adoption of qEEG markers., K.I. is supported by Ajuts Destinats a Universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802). A.P. is supported by Fundación Tatiana-Proyectos en Neurociencia (Grant 2022-1514). R.Z. is supported by Neurotech-EU (Grant agreement ID: 101035817). M.D. is funded by the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS), H2020 European Union's Horizon 2020 research and innovation programme under grant agreement No. 848077 and 899986, Jerôme Lejeune Foundation #2002. The APC was funded by Fundación Tatiana¿Proyectos en Neurociencia (Grant 20.22-15.14).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Modeling the impact of neuromorphological alterations in Down syndrome on fast neural oscillations

  • Clusella, Pau
  • Manubens-Gil, Linus, 1989-
  • García Ojalvo, Jordi
  • Dierssen, Mara
Cognitive disorders, including Down syndrome (DS), present significant morphological alterations in neuron architectural complexity. However, the relationship between neuromorphological alterations and impaired brain function is not fully understood. To address this gap, we propose a novel computational model that accounts for the observed cell deformations in DS. The model consists of a cross-sectional layer of the mouse motor cortex, composed of 3000 neurons. The network connectivity is obtained by accounting explicitly for two single-neuron morphological parameters: the mean dendritic tree radius and the spine density in excitatory pyramidal cells. We obtained these values by fitting reconstructed neuron data corresponding to three mouse models: wild-type (WT), transgenic (TgDyrk1A), and trisomic (Ts65Dn). Our findings reveal a dynamic interplay between pyramidal and fast-spiking interneurons leading to the emergence of gamma activity (∼40 Hz). In the DS models this gamma activity is diminished, corroborating experimental observations and validating our computational methodology. We further explore the impact of disrupted excitation-inhibition balance by mimicking the reduction recurrent inhibition present in DS. In this case, gamma power exhibits variable responses as a function of the external input to the network. Finally, we perform a numerical exploration of the morphological parameter space, unveiling the direct influence of each structural parameter on gamma frequency and power. Our research demonstrates a clear link between changes in morphology and the disruption of gamma oscillations in DS. This work underscores the potential of computational modeling to elucidate the relationship between neuron architecture and brain function, and ultimately improve our understanding of cognitive disorders., PC and JGO have received funding from the Future and Emerging Technologies Programme (FET) of the European Union’s Horizon 2020 research and innovation programme (project NEUROTWIN, grant agreement No 101017716). JGO was also financially supported by the Spanish Ministry of Science and Innovation (project reference PID2021-127311NB-I00), the FEDER funds of the Spanish State Research Agency (project reference MICIN/AEI/10.13039/501100011033/FEDER), the Maria de Maeztu Programme for Units of Excellence in R\&D of the Spanish State Research Agency (project reference CEX2018-000792-M), and by the ICREA Academia program. LMG was supported by the National Natural Science Foundation of China (RFIS-I grant, reference 32350410413). MD acknowledges financial support from the Spanish Ministry of Science and Innovation (projects CPP2022-009659 and RTC2019-007329-1), the Spanish State Research Agency (project INTO-DS, reference PID2022-141900OB-I00), the Marato-TV3 Foundation (202212-30-31-32), and the European Comission Horizon 2020 programme (projects H2020-899986 and GO-DS21-848077). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Down syndrome and obesity management: lifestyle observations made in the framework of the GO-DS21 project and clinical recommendations

  • Gomis González, Maria, 1988-
  • Chan, Li
  • Hiance-Delahaye, Anna
  • Dierssen, Mara
  • Strydom, Andre
  • Torre Fornell, Rafael de la
Introduction/background: Individuals with Down syndrome (DS) face a higher and earlier risk of overweight and/or obesity than the general population, influenced by factors like limited physical activity, suboptimal diet, stress, and sleep disorders. Despite the impact these lifestyle factors can have, there is a significant lack of robust, evidence-based guidelines for managing overweight and obesity in these individuals, particularly for the adult population. Results: Based on findings from an observational study across three European sites, within the EU Horizon-2020 GO-DS21 project, in this short communication, we highlight some key insights for developing effective prevention and management strategies for overweight and obesity in people with Down syndrome. Conclusions: In general terms, effective overweight and obesity management demands a holistic approach, integrating tailored diet and physical activity and actively addressing co-occurring health conditions. Moreover, the active participation of the family and peers is crucial for promoting sustainable healthy habits and for enhancing the overall quality of life of people with Down syndrome., This work (Gene overdosage and comorbidities during the early lifetime in Down syndrome project) was supported by the EU Horizon 2020 program (Grant agreement ID: 848077).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A novel way to use cross-validation to measure connectivity by machine learning allows epilepsy surgery outcome prediction

  • Ivankovic, Karla
  • Principe, Alessandro
  • Montoya Gálvez, Justo
  • Manubens-Gil, Linus, 1989-
  • Zucca, Riccardo
  • Villoslada, Pablo
  • Dierssen, Mara
  • Rocamora Zúñiga, Rodrigo Alberto
The rate of success of epilepsy surgery, ensuring seizure-freedom, is limited by the lack of epileptogenicity biomarkers. Previous evidence supports the critical role of functional connectivity during seizure generation to characterize the epileptogenic network (EN). However, EN dynamics is highly variable across patients, hindering the development of diagnostic biomarkers. Without relying on specific connectivity variables, we focused on a general hypothesis that the EN undergoes the greatest magnitude of connectivity change during seizure generation, compared to other brain networks. To test this hypothesis, we developed a novel method for quantifying connectivity change between network states and applied it to identify surgical resection areas. A network state was represented by random snapshots of connectivity within a defined time interval of an intracranial EEG recording. A binary classifier was applied to classify two network states. The classifier generalization performance estimated by cross-validation was employed as a continuous measure of connectivity change. The algorithm generated a network by iteratively adding nodes until the connectivity change magnitude decreased. The resulting network was compared to the surgical resection, and the overlap score was used to predict post-surgical outcomes. The framework was evaluated in a consecutive cohort of 21 patients with a post-surgical follow-up of minimum 3 years. The best overlap between connectivity change networks and resections was obtained at the transition from pre-seizure to seizure (surgical outcome prediction ROC-AUC=90.3 %). However, all patients except one were correctly classified when considering the most informative time intervals. Time intervals proportional to seizure length were more informative than the almost universally used fixed intervals. This study demonstrates that connectivity can be successfully classified with a machine learning analysis and provide information for distinguishing a separate epileptogenic functional network. In summary, the connectivity change analysis could accurately identify epileptogenic networks validated by surgery outcome classification. Connectivity change magnitude at seizure transition could potentially serve as an EN biomarker. The tool provided by this study may aid surgical decision-making., FLAG–ERA JTC 2017 Human Brain Project, CAUSALTOMICS (PCI2018–092860) (AP, KI). Fundación Tatiana - Proyectos en Neurociencia - Grant 2022–1514 (AP). Ajuts destinats a universitats, centres de recerca i fundacions hospitalàries per contractar personal investigador novell per a l'any 2022 (FI-DGR Grant Number: 14802) (KI). Emergent Cluster of the Human Brain (CECH) and the European Regional Development Fund (FEDER) 001-P-001682 (RZ). The lab of MD was supported by the Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). Agencia Estatal de Investigación (PID2019–110755RB-I00/AEI/10.13039/501100011033) (MD). The European Union's Horizon 2020 Research and Innovation Program under grant agreement No 848077 (MD). NIH (Grant Number: 1R01EB 028159–01) (MD). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Understanding obesity in individuals with down syndrome: caregiver perceptions, awareness, and motivation

  • Cahill, Thomas
  • Nalesso, Valerie
  • Clarke, Pat
  • Martínez de Lagrán Cabredo, María
  • Strydom, Andre
  • Chan, Li
  • Potier, Marie-Claude
  • Beckers, Johannes
  • Langohr, Klaus
  • Liò, Pietro
  • Torre Fornell, Rafael de la
  • Forcano, Laura
  • Hiance-Delahaye, Anna
  • Herault, Yann
  • Dierssen, Mara
Background: Individuals with Down syndrome (DS) are at an increased risk of obesity and, subsequently, its cardiometabolic and cognitive impacts. Caregivers play a critical role in managing health, yet their perceptions and behaviors have been poorly characterized. Methods: We performed a cross-sectional online survey of caregivers (n = 764) taking care of 48% females and 52% males with DS, conducted across European populations, predominantly in Spain and France. We assessed perceived obesity, perceived harmfulness of current weight, professional consultation, and confidence in promoting healthy behaviors. Associations were examined using chi-square tests, correlation analysis, and ordinal and logistic regression models. Results: Around one-third (32%) of caregivers perceived their family member with DS with obesity. Perceived obesity changed with age and was more frequently reported in female family members with DS. Awareness of general metabolic risk factors was high among caregivers, but half of respondents were unaware that abdominal fat affects brain health. Consultation with healthcare professionals was uncommon (57% "Never/Rarely/Sometimes") even among those perceived with obesity. Conclusions: Caregivers demonstrate good general awareness about high energy food risks but limited knowledge of the link between obesity and brain health. Enhancing caregiver education and supporting behavioral change could promote healthier lifestyles in families with individuals with DS., This project received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 848077 (GO-DS21). The lab of M.D. and of RTF are recognized by the Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033), the Generalitat de Catalunya through the CERCA program and the EMBL partnership. KL received funding from PID2023-148033OB-C21 of the Ministerio de Ciencia, Innovación y Universidades (Spain; MICIU/AEI/10.13039/501100011033) and the European Regional development Fund (FEDER). LC received funding from Wellcome Trust grant (217543/Z/19/Z), and Barts Charity grant (G-002162). AS received funding from Medical Research Council grants (MR/S011277/1, MR/S005145/1, and MR/R024901/1) and the Jerome LeJeune Foundation. MD received funding from the Agencia Estatal de Investigación (PID2022-141900OB-I00 funded by MICIU/AEI/10.13039/501100011033/ERDF, EU), Fundació La Marató-TV3 (#202212-30), Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1, and CPP2022-009659 funded by MCIN/AEI/10.13039/501100011033 and EU's 'NextGenerationEU'/PRTR'). The CIBER of Rare Diseases is an initiative of the ISCIII. RDT and LF research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Environmental enrichment induces epigenomic and genome organization changes relevant for cognition

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomic profiling reveals mitochondrial dysfunction in the cerebellum of transgenic mice overexpressing DYRK1A, a Down syndrome candidate gene

  • Ortega, Mireia
  • De Toma, Ilario
  • Fernández-Blanco, Álvaro
  • Calderón Moruno, Anna
  • Barahona, Lucía
  • Trullàs, Ramón
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Introduction: DYRK1A is a dual-specificity kinase that is overexpressed in Down syndrome (DS) and plays a key role in neurogenesis, neuronal differentiation and function, cognitive phenotypes, and aging. Dyrk1A has also been implicated in cerebellar abnormalities observed in association with DS, and normalization of Dyrk1A dosage rescues granular and Purkinje cell densities in a trisomic DS mouse model. However, the underlying molecular mechanisms governing these processes are unknown. Methods: To shed light on the effects of Dyrk1A overexpression in the cerebellum, here we investigated the cerebellar proteome in transgenic Dyrk1A overexpressing mice in basal conditions and after treatment with green tea extract containing epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor. Results and discussion: Our results showed that Dyrk1A overexpression alters oxidative phosphorylation and mitochondrial function in the cerebellum of transgenic mice. These alterations are significantly rescued upon EGCG-containing green tea extract treatment, suggesting that its effects in DS could depend in part on targeting mitochondria, as shown by the partially restoration by the treatment of the increased mtDNA copy number in TG non-treated mice., This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Framework Programme under grant agreement no 848077. This reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (grant number 2002), NIH Blueprint for Neuroscience Research (grant number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and EU Joint Programme—Neurodegenerative Disease Research (Heroes AC170006). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Comparison of COVID-19 and non-COVID-19 pneumonia in Down syndrome

  • Real de Asua, Diego
  • Mayer, Miguel Ángel, 1960-
  • Ortega, María del Carmen
  • Borrel, Jose M.
  • Bermejo, Teresa de Jesús
  • González Lamuño, Domingo
  • Manso, Coral
  • Moldenhauer, Fernando
  • Carmona Iragui, María
  • Hüls, Anke
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID-19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19., The lab of M.D. is supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). We also acknowledge the support of the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848077, Jerôme Lejeune Foundation (No 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), JPND Heroes project. CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) and CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN) are initiatives of the ISCIII. D.R.A. is partially supported by the Fondo de Investigaciones Sanitarias (FIS grant PI19/00634, European Fund for Regional Development—EFRD) and the Foundation Jérôme Lejeune (grant no. 1777-2018). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). AH was supported by the HERCULES Center (NIEHS P30ES019776) and by the LuMind IDSC Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Fluorescent transgenic mouse models for whole-brain imaging in health and disease

  • Arias, Adrian
  • Manubens-Gil, Linus, 1989-
  • Dierssen, Mara
A paradigm shift is occurring in neuroscience and in general in life sciences converting biomedical research from a descriptive discipline into a quantitative, predictive, actionable science. Living systems are becoming amenable to quantitative description, with profound consequences for our ability to predict biological phenomena. New experimental tools such as tissue clearing, whole-brain imaging, and genetic engineering technologies have opened the opportunity to embrace this new paradigm, allowing to extract anatomical features such as cell number, their full morphology, and even their structural connectivity. These tools will also allow the exploration of new features such as their geometrical arrangement, within and across brain regions. This would be especially important to better characterize brain function and pathological alterations in neurological, neurodevelopmental, and neurodegenerative disorders. New animal models for mapping fluorescent protein-expressing neurons and axon pathways in adult mice are key to this aim. As a result of both developments, relevant cell populations with endogenous fluorescence signals can be comprehensively and quantitatively mapped to whole-brain images acquired at submicron resolution. However, they present intrinsic limitations: weak fluorescent signals, unequal signal strength across the same cell type, lack of specificity of fluorescent labels, overlapping signals in cell types with dense labeling, or undetectable signal at distal parts of the neurons, among others. In this review, we discuss the recent advances in the development of fluorescent transgenic mouse models that overcome to some extent the technical and conceptual limitations and tradeoffs between different strategies. We also discuss the potential use of these strains for understanding disease., The lab of MD was supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). This research was funded by the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No. 848077. This reflects only the author’s view, and the European Commission is not responsible for any use that may be made of the information it contains. Jerôme Lejeune Foundation (Grant Number 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), and JPND (Heroes AC170006). The CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Astrocytopathy is associated with CA1 synaptic dysfunction in a mouse model of Down syndrome

  • Fernández-Blanco, Álvaro
  • González-Arias, Candela
  • Sierra, Cesar
  • Zamora Moratalla, Alfonsa
  • Perea, Gertrudis
  • Dierssen, Mara
Brain pathophysiology in Down syndrome (DS), the most common genetic cause of intellectual disability, has traditionally been considered a consequence of neuronal dysfunction. However, although it is well documented that astrocytes play a critical role in brain homeostasis, synaptic regulation, and neuronal support, and their malfunction has been associated with the onset and progression of different neurological disorders, only a few studies have addressed whether astrocyte dysfunction can contribute to the DS pathophysiology. Astrocytes are increased in number and size, and show increased levels of expression of astroglial markers like S100ß and GFAP. In this study, we detected a region-specific increase in astrocyte population in CA1 and, to a lesser extent, in the dentate gyrus. Single-nucleus transcriptomic profiling identified markers associated with reactive astroglia, synaptic transmission, and neuroinflammation in trisomic astrocytes. Functional analysis revealed abnormal Ca2+ oscillations in trisomic astrocytes and impaired astrocyte-to-neuron communication in CA1, the most affected subregion, leading to astrocyte-mediated excitatory synaptic depression. Our findings demonstrate that astrocytes play an active and critical role in the pathophysiology of DS, not only as reactive responders to neuronal injury but as key contributors to the disease process itself. This astrocytic dysfunction presents a region-specific distribution within the hippocampus, suggesting localized vulnerability and complex glial involvement in DS-related neuropathology., The lab of MD is supported by the Secretaria d¿Universitats i Recerca del Departament d'Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926). We also acknowledge the support of the Agencia Estatal de Investigación (PID2022-141900OB-I00 INTO-DS funded by MICIU/AEI/10.13039/501100011033/FEDER, UE). This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 848077). The publication is part of the grant PRE2018-084504, funded by MCIN/AEI/10.13039/501100011033 and by the FSE+ (AFB). Additionally, we have been supported by Fundació La Marató TV3 (201620-31 and 225619), and by PID2022-142617NB-I00 and PID2019-106579RB-I00 funded by MCIN/AEI/10.13039/501100011033 to G.P.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dietary patterns and lifestyle factors as determinants of body mass index and body composition in individuals with Down Syndrome-A study across three clinical sites

  • Gomis González, Maria, 1988-
  • Boronat Rigol, Anna, 1990-
  • Langohr, Klaus
  • Bianchi, Leda A.
  • Wells, Jasmine
  • Tamayo-Elizalde, Miren
  • Ben Smida, Inés
  • Verdun, Laude De
  • Chan, Li
  • Hiance-Delahaye, Anna
  • Strydom, Andre
  • Torre Fornell, Rafael de la
  • Go-Ds Consortium
Background/Objectives: It is often reported in the literature that the prevalence of obesity is high in individuals with Down Syndrome (DS). This study aims to assess how lifestyle factors-diet quality, nutrient intake or physical activity-contribute to weight gain. Methods: 230 males/females with DS, aged 12-45 years, were recruited across three geographically independent sites. A total of 185 participants were considered for this analysis and classified into normal-weight, overweight, and obese categories. Diet quality and nutrient intake were calculated using country-specific FFQs. Physical activity was assessed with the Minnesota Leisure Time Activity Questionnaire. Body composition measures were obtained with a bioimpedance scale. Results: The study corroborates a higher prevalence (%) of overweight/obesity in our DS cohort compared to the general population. Higher BMIs were significantly correlated with older age (p < 0.001), lower physical activity (p < 0.05), higher parental BMIs (p < 0.001, mother's BMI; p < 0.05, father's BMI), and increased adiposity indicators. Excess body weight showed an inverse association only with protein intake (p < 0.001). No significant differences emerged in total caloric or other macronutrients intake across BMI categories. However, notable differences in dietary patterns were observed among the three countries, reflecting cultural influences. A smaller exploratory sub-study suggested a potential relationship between higher IQ scores and better diet quality (p < 0.05). Conclusions: These findings provide new insights into contributors to overweight/obesity in DS people, indicating an influence of age, physical activity, familial factors, and body composition. Higher protein intake and culturally adapted lifestyle interventions may contribute to improving weight-related outcomes., The Gene Overdosage and Comorbidities During the Early Lifetime in Down Syndrome (GO-DS21) project has received funding from the European Union's Horizon research and innovation program under grant agreement n- SC1848077. The CIBEROBN is an initiative of the ISCIII. This work was supported by grants from DIUE de la Generalitat de Catalunya (2021SGR00253) and from the Ministerio de Ciencia, Innovanción y Universidades (PID2023-148033OB-C21). LFC received funding from a Medical Research Council UK and Academy of Medical Sciences fellowship grant (G0802796), aWellcome Trust grant (217543/Z/19/Z), BBSRC (BB/W018276/1), and Barts Charity grant (G-002162). AS received funding from the Jerome Lejeune Foundation, and the MRC (grant numbers MR/S011277/1, MR/S005145/1, and MR/R024901/1).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Beyond quiescent and active: Intermediate microglial transcriptomic states in a mouse model of down syndrome

  • Fernández Blanco, Álvaro
  • Sierra, Cesar
  • Tejido, Clara
  • Dierssen, Mara
Research on microglia in Down syndrome (DS) has shown that microglial activation, increased inflammatory gene expression, and oxidative stress occur at different ages in DS brains. However, most studies resulted in simplistic definitions of microglia as quiescent or active, ignoring potential intermediate states. Indeed, recent work on microglial cells in young DS brains indicated that those evolve through different intermediate activation phenotypes before reaching a fully activated state. Here we used single nucleus RNA sequencing, to examine how trisomy affects microglial states in the Ts65Dn mouse model of DS. Despite no substantial changes in the proportion of glial populations, differential expression analysis revealed cell type-specific gene expression changes, most notably in astroglia, microglia, and oligodendroglia. Focusing on microglia, we identified differential expression of genes associated with different microglial states, including disease-associated microglia (DAMs), activated response microglia (ARMs), and human Alzheimer's disease microglia (HAMs), in trisomic microglia. Furthermore, pseudotime analysis reveals a unique reactivity profile in Ts65Dn microglia, with fewer in a homeostatic state and more in an intermediate aberrantly reactive state than in euploid microglia. This comprehensive understanding of microglial transcriptional dynamics sheds light on potential pathogenetic mechanisms but also possible avenues for therapy for neurodevelopmental disorders., The lab of MD is recognized by the Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement de la Generalitat de Catalunya (Grups consolidats 2023). This project has received funding from the Agencia Estatal de Investigación (PID2019-110755RB-I00/AEI/10.13039/501100011033; PID2022-141900OB-I00 INTO-DS), from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848077 and 899986, Jerôme Lejeune Foundation #2002, Fundació La Marató-TV3 (#2016/20-30), JPND Heroes Ministerio de Ciencia Innovación y Universidades (RTC2019-007230-1, RTC2019-007329-1; and CPP2022-009659). The CIBER of Rare Diseases is an initiative of the ISCIII. C.S. received the FI grant from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya, and A.F.B. received an FPI-SO fellowship (PRE2018-084504).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

  • Hüls, Anke
  • Dierssen, Mara
  • Mayer, Miguel Ángel, 1960-
  • T21RS COVID-19 Initiative
Background: Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. Methods: The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. Findings: The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Interpretation: Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Funding: Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

  • Hüls, Anke|||0000-0002-6005-417X
  • Costa, Alberto C. S.
  • Dierssen, Mara|||0000-0003-0853-6865
  • Baksh, Asaad|||0000-0001-6596-2145
  • Bargagna, Stefania
  • Baumer, Nicole
  • Brandão, Ana Claudia
  • Carfi, Angelo|||0000-0002-9837-7003
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Chicoine, Brian|||0000-0002-1520-3893
  • Ghosh, Sujay
  • Lakhanpaul, Monica
  • Manso, Coral
  • Mayer, Miguel-Angel
  • Ortega, Maria del Carmen
  • de Asua, Diego Real
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Russell, Lauren Ashley
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Sherman, Stephanie L.
  • Strydom, Andre
Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of covid-19 and non-covid-19 pneumonia in down syndrome

  • Real de Asua, Diego
  • Mayer, Miguel Angel|||0000-0003-0362-6298
  • Del Carmen Ortega, María
  • Borrel, Jose M.
  • de Jesús Bermejo, Teresa
  • González-lamuño, Domingo|||0000-0002-7578-241X
  • Manso, Coral
  • Moldenhauer, Fernando|||0000-0002-6259-8226
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Hüls, Anke|||0000-0002-6005-417X
  • Sherman, Stephanie L.
  • Strydom, Andre
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Dierssen, Mara|||0000-0003-0853-6865
Whether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID- 19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The clinical and neuropathological features of sporadic (Late-onset) and genetic forms of alzheimer's disease

  • Rujeedawa, Tanzil|||0000-0002-7089-1684
  • Carrillo Félez, Eva
  • Clare, Isabel C.H.|||0000-0002-5385-008X
  • Fortea, Juan|||0000-0002-1340-638X
  • Strydom, Andre
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Coppus, Antonia
  • Levin, Johannes|||0000-0001-5092-4306
  • Zaman, Shahid
The purpose of this review is to compare and highlight the clinical and pathological aspects of genetic versus acquired Alzheimer's disease: Down syndrome-associated Alzheimer's disease in (DSAD) and Autosomal Dominant Alzheimer's disease (ADAD) are compared with the late-onset form of the disease (LOAD). DSAD and ADAD present in a younger population and are more likely to manifest with non-amnestic (such as dysexecutive function features) in the prodromal phase or neurological features (such as seizures and paralysis) especially in ADAD. The very large variety of mutations associated with ADAD explains the wider range of phenotypes. In the LOAD, age-associated comorbidities explain many of the phenotypic differences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deficits in neuronal architecture but not over-inhibition are main determinants of reduced neuronal network activity in a mouse model of overexpression of Dyrk1A

  • Manubens-Gil, Linus|||0000-0003-2036-2204
  • Pons-Espinal, Meritxell|||0000-0003-0832-2963
  • Gener, Thomas|||0000-0001-9209-9228
  • Ballesteros-Yañez, Inmaculada|||0000-0003-4362-027X
  • Martínez de Lagrán, María|||0000-0002-0836-6491
  • Dierssen, Mara|||0000-0003-0853-6865
In this study, we investigated the impact of Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) overexpression, a gene associated with Down syndrome, on hippocampal neuronal deficits in mice. Our findings revealed that mice overexpressing Dyrk1A (TgDyrk1A; TG) exhibited impaired hippocampal recognition memory, disrupted excitation-inhibition balance, and deficits in long-term potentiation (LTP). Specifically, we observed layer-specific deficits in dendritic arborization of TG CA1 pyramidal neurons in the stratum radiatum. Through computational modeling, we determined that these alterations resulted in reduced storage capacity and compromised integration of inputs, with decreased high γ oscillations. Contrary to prevailing assumptions, our model suggests that deficits in neuronal architecture, rather than over-inhibition, primarily contribute to the reduced network. We explored the potential of environmental enrichment (EE) as a therapeutic intervention and found that it normalized the excitation-inhibition balance, restored LTP, and improved short-term recognition memory. Interestingly, we observed transient significant dendritic remodeling, leading to recovered high γ. However, these effects were not sustained after EE discontinuation. Based on our findings, we conclude that Dyrk1A overexpression-induced layer-specific neuromorphological disturbances impair the encoding of place and temporal context. These findings contribute to our understanding of the underlying mechanisms of Dyrk1A-related hippocampal deficits and highlight the challenges associated with long-term therapeutic interventions for cognitive impairments.